MeSH term
Frequency | Condition_Probility | Female | 777 | 0.0 |
Humans | 2403 | 1.0 |
Pregnancy | 54 | 0.0 |
Pregnancy Rate | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Diagnosis, Differential | 13 | 0.0 |
Adolescent | 185 | 1.0 |
Adult | 549 | 0.0 |
Child | 161 | 1.0 |
Child, Preschool | 84 | 0.0 |
Male | 772 | 0.0 |
Middle Aged | 464 | 0.0 |
Movement/*physiology | 9 | 23.0 |
Rotation | 7 | 15.0 |
Area Under Curve | 29 | 6.0 |
Creatinine/blood | 6 | 1.0 |
Drug Monitoring | 7 | 15.0 |
*Graft Rejection | 4 | 4.0 |
*Immunosuppression | 2 | 2.0 |
*Lung Transplantation | 4 | 14.0 |
Research Support, Non-U.S. Gov't | 1146 | 0.0 |
Binding Sites | 125 | 1.0 |
Cell Cycle/drug effects | 4 | 0.0 |
Cell Division/drug effects | 26 | 0.0 |
DNA/metabolism | 5 | 0.0 |
Drug Design | 12 | 3.0 |
Drug Screening Assays, Antitumor | 8 | 2.0 |
Mice | 198 | 0.0 |
Models, Molecular | 88 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 115 | 1.0 |
Structure-Activity Relationship | 90 | 3.0 |
Aged | 304 | 0.0 |
Algorithms | 8 | 2.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Antigens, CD/immunology | 2 | 0.0 |
Cadaver | 15 | 6.0 |
*Chimeric Proteins | 2 | 20.0 |
Comparative Study | 297 | 1.0 |
Continental Population Groups | 6 | 3.0 |
Cyclosporine/blood/*pharmacokinetics/*therapeutic use | 3 | 100.0 |
Drug Monitoring/methods | 15 | 55.0 |
Drug Therapy, Combination | 12 | 0.0 |
Feasibility Studies | 8 | 3.0 |
Immunosuppressive Agents/blood/pharmacokinetics/therapeutic use | 9 | 90.0 |
Intestinal Absorption/*physiology | 3 | 12.0 |
Kidney Transplantation/*immunology | 15 | 7.0 |
Living Donors | 2 | 4.0 |
Predictive Value of Tests | 22 | 1.0 |
Reproducibility of Results | 37 | 2.0 |
Tissue Donors | 4 | 1.0 |
Kidney Transplantation/immunology/*physiology | 4 | 21.0 |
Metabolic Clearance Rate | 9 | 2.0 |
Sample Size | 2 | 6.0 |
Time Factors | 121 | 1.0 |
Amino Acid Sequence | 281 | 1.0 |
Antibody Formation | 11 | 2.0 |
Antibody Specificity | 33 | 2.0 |
Binding Sites/immunology | 4 | 6.0 |
Factor VIII/*immunology | 6 | 31.0 |
Precipitin Tests | 30 | 1.0 |
Recombinant Proteins/immunology | 8 | 2.0 |
Dose-Response Relationship, Drug | 63 | 1.0 |
Apoptosis | 5 | 0.0 |
Cell Line | 173 | 0.0 |
Insulin-Like Growth Factor I/pharmacology | 4 | 2.0 |
Mutation | 55 | 0.0 |
Somatomedins/metabolism | 2 | 6.0 |
Tumor Cells, Cultured | 92 | 0.0 |
Binding, Competitive | 36 | 1.0 |
*DNA, Recombinant | 2 | 5.0 |
Glutamic Acid/metabolism | 4 | 9.0 |
Epidemiology, Molecular | 2 | 2.0 |
*Evolution, Molecular | 9 | 2.0 |
Phylogeny | 32 | 2.0 |
RNA, Viral/genetics | 3 | 3.0 |
Vaccination | 2 | 1.0 |
Base Sequence | 201 | 0.0 |
Cell Membrane/chemistry | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Molecular Sequence Data | 366 | 1.0 |
RNA, Messenger/biosynthesis | 11 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 618 | 1.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Blood Proteins/*chemistry | 2 | 7.0 |
Enzyme-Linked Immunosorbent Assay | 51 | 1.0 |
Models, Biological | 30 | 0.0 |
Phosphatidylserines/chemistry | 2 | 25.0 |
Point Mutation | 11 | 0.0 |
Protein Binding | 92 | 1.0 |
Protein Structure, Tertiary | 78 | 1.0 |
Recombinant Proteins/chemistry | 22 | 6.0 |
Sequence Homology, Amino Acid | 86 | 1.0 |
Carrier Proteins/genetics | 7 | 1.0 |
Down-Regulation | 11 | 0.0 |
Gene Expression Profiling | 4 | 0.0 |
Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Melanocytes/metabolism | 3 | 7.0 |
Melanoma/*genetics/secondary | 2 | 14.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Proteins/genetics | 4 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 2 | 1.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
Up-Regulation | 9 | 0.0 |
English Abstract | 182 | 1.0 |
Follow-Up Studies | 57 | 1.0 |
*Helicobacter pylori | 2 | 1.0 |
Recurrence | 23 | 1.0 |
*Respiration | 2 | 5.0 |
Animals | 630 | 0.0 |
Blotting, Western | 33 | 0.0 |
Cell Nucleus/metabolism | 9 | 0.0 |
Chromatography, Gel | 22 | 2.0 |
Culture Media, Serum-Free | 3 | 0.0 |
Drosophila melanogaster | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 79 | 2.0 |
Luciferases/metabolism | 3 | 0.0 |
RNA/metabolism | 3 | 0.0 |
Transcription Factors/*metabolism | 7 | 0.0 |
*Transcription, Genetic | 10 | 0.0 |
History, 20th Century | 4 | 2.0 |
Infant | 48 | 0.0 |
Administration, Oral | 15 | 1.0 |
Chromatography, High Pressure Liquid | 40 | 2.0 |
Dogs | 21 | 1.0 |
Magnetic Resonance Spectroscopy | 32 | 6.0 |
Rabbits | 65 | 2.0 |
Rats | 123 | 0.0 |
Rats, Wistar | 11 | 0.0 |
Species Specificity | 38 | 1.0 |
Spectrometry, Mass, Fast Atom Bombardment | 2 | 7.0 |
Tissue Distribution | 14 | 0.0 |
Tritium | 5 | 2.0 |
Chickens | 16 | 2.0 |
Complement 1s/metabolism | 3 | 25.0 |
Complement 2/*metabolism | 16 | 94.0 |
Complement 3/metabolism | 31 | 12.0 |
Complement 5/metabolism | 8 | 18.0 |
Conserved Sequence | 17 | 1.0 |
Hydrolysis | 21 | 2.0 |
Oxidation-Reduction | 24 | 1.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
Receptors, Cell Surface/chemistry/*metabolism | 2 | 7.0 |
Sequence Alignment | 52 | 1.0 |
Antigens, Surface/*metabolism | 2 | 3.0 |
COS Cells | 14 | 0.0 |
Cell Differentiation/*physiology | 3 | 1.0 |
Glycosylation | 18 | 1.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
Muscles/metabolism | 5 | 5.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 4 | 1.0 |
Receptors, Cholinergic/metabolism | 2 | 10.0 |
Circular Dichroism | 6 | 1.0 |
Dimethyl Sulfoxide/pharmacology | 2 | 2.0 |
Protein Conformation | 94 | 3.0 |
Solubility | 19 | 1.0 |
Spectrum Analysis, Mass | 11 | 1.0 |
COS Cells/metabolism | 2 | 3.0 |
Cercopithecus aethiops | 10 | 0.0 |
Complement Factor B/metabolism | 9 | 21.0 |
Fluorescent Antibody Technique | 34 | 1.0 |
Hamsters | 21 | 0.0 |
Transfection | 75 | 0.0 |
Apoptosis/drug effects | 5 | 0.0 |
Blotting, Northern | 28 | 0.0 |
Cell Transformation, Neoplastic/drug effects | 2 | 5.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Flow Cytometry | 24 | 0.0 |
Immunoblotting | 30 | 1.0 |
Phenotype | 83 | 0.0 |
Magnetic Resonance Imaging | 15 | 1.0 |
Tomography, X-Ray Computed | 22 | 2.0 |
Crystallization | 40 | 17.0 |
Macromolecular Substances | 34 | 1.0 |
Cervical Vertebrae | 4 | 40.0 |
Immunohistochemistry | 36 | 0.0 |
*Kidney Transplantation | 17 | 3.0 |
Prospective Studies | 55 | 1.0 |
Calcium/*metabolism | 13 | 1.0 |
Cell Differentiation | 27 | 0.0 |
Lipids/metabolism | 7 | 2.0 |
*Membrane Proteins | 6 | 0.0 |
Microscopy, Fluorescence | 13 | 0.0 |
Phosphatidylserines/metabolism | 8 | 15.0 |
Phospholipids/metabolism | 17 | 8.0 |
Blood Pressure/physiology | 4 | 2.0 |
Elasticity | 6 | 12.0 |
Regression Analysis | 22 | 1.0 |
Statistics | 10 | 2.0 |
Biological Transport | 9 | 0.0 |
Catalytic Domain | 14 | 4.0 |
Cell Membrane/enzymology | 7 | 2.0 |
Cytosol/*enzymology | 5 | 9.0 |
Enzyme Activation | 30 | 0.0 |
Hydrophobicity | 2 | 2.0 |
Phospholipases A/*chemistry/metabolism | 3 | 75.0 |
*Models, Cardiovascular | 4 | 12.0 |
Signal Processing, Computer-Assisted | 2 | 4.0 |
Amino Acid Motifs | 6 | 0.0 |
Cell Division | 18 | 0.0 |
Kinetics | 131 | 1.0 |
Mice, Nude | 7 | 0.0 |
Sequence Analysis, Protein | 4 | 2.0 |
Myocardium/cytology | 2 | 6.0 |
Patch-Clamp Techniques | 2 | 0.0 |
Phosphatidylinositol 4,5-Diphosphate/*metabolism | 3 | 20.0 |
Phospholipase C/*metabolism | 3 | 2.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 11 | 0.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
Yeasts/metabolism | 2 | 11.0 |
Arteries/*physiology | 4 | 36.0 |
Calcium/blood | 3 | 1.0 |
Compliance | 4 | 25.0 |
Heart Rate | 5 | 2.0 |
Pulse | 2 | 9.0 |
*Renal Dialysis | 5 | 1.0 |
Chromatography, High Pressure Liquid/*methods | 11 | 8.0 |
Spectrometry, Fluorescence | 9 | 2.0 |
Postoperative Period | 11 | 3.0 |
Questionnaires | 4 | 0.0 |
Rectal Neoplasms/*surgery | 3 | 60.0 |
Epitope Mapping | 12 | 4.0 |
Epitopes/chemistry/metabolism | 2 | 20.0 |
Evolution, Molecular | 8 | 1.0 |
Factor VIII/chemistry/*immunology | 3 | 100.0 |
Hemophilia A/immunology | 3 | 37.0 |
Immunoglobulins, Heavy-Chain/*genetics | 3 | 2.0 |
Multigene Family | 11 | 1.0 |
Plasmids | 18 | 1.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 6 | 3.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
Hela Cells | 36 | 0.0 |
Mitosis | 2 | 0.0 |
Phosphorylation | 26 | 0.0 |
Recombinant Proteins/metabolism | 14 | 0.0 |
Alkaline Phosphatase/blood | 2 | 1.0 |
Bilirubin/blood | 2 | 2.0 |
Proportional Hazards Models | 2 | 0.0 |
Safety | 3 | 2.0 |
Case-Control Studies | 26 | 0.0 |
Cell Culture Techniques | 5 | 1.0 |
Cytokines/*pharmacology | 5 | 1.0 |
Autoantibodies/*analysis | 5 | 2.0 |
Cyclophosphamide/therapeutic use | 2 | 2.0 |
Immunosuppressive Agents/therapeutic use | 4 | 1.0 |
Mutation, Missense | 3 | 0.0 |
Enzyme Activation/immunology | 3 | 2.0 |
Epitopes/*immunology | 9 | 4.0 |
Factor VIII/*immunology/metabolism | 4 | 57.0 |
Factor Xa/*metabolism | 2 | 9.0 |
Isoantibodies/*immunology | 4 | 10.0 |
Protein Binding/immunology | 2 | 1.0 |
*CDC2-CDC28 Kinases | 3 | 0.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 8 | 1.0 |
Purines/*pharmacology | 2 | 11.0 |
Tumor Cells, Cultured/drug effects/enzymology | 2 | 6.0 |
Aged, 80 and over | 86 | 0.0 |
*Disease Outbreaks | 3 | 5.0 |
Genotype | 72 | 0.0 |
Sequence Analysis, DNA | 27 | 0.0 |
Viral Proteins/genetics | 3 | 4.0 |
Alleles | 92 | 1.0 |
Amino Acids/chemistry | 5 | 4.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
Heterozygote | 30 | 1.0 |
Polymorphism, Genetic | 60 | 1.0 |
Russia | 2 | 2.0 |
Blood Flow Velocity | 2 | 2.0 |
Regional Blood Flow | 3 | 2.0 |
Sensitivity and Specificity | 32 | 0.0 |
Gene Therapy | 2 | 0.0 |
Hemophilia A/*immunology/therapy | 2 | 66.0 |
Immune Tolerance | 3 | 1.0 |
Immunotherapy | 2 | 0.0 |
Anticoagulants/*pharmacology | 3 | 3.0 |
Bleeding Time | 2 | 1.0 |
Depression, Chemical | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Factor VIII/*metabolism | 5 | 8.0 |
Partial Thromboplastin Time | 4 | 2.0 |
Protein Binding/drug effects | 7 | 1.0 |
Annexin A5/metabolism | 2 | 2.0 |
Antibodies, Monoclonal/pharmacology | 4 | 0.0 |
Cells, Cultured | 134 | 0.0 |
Factor X/*metabolism | 2 | 8.0 |
Cell Membrane/genetics/metabolism | 2 | 14.0 |
Molecular Structure | 28 | 3.0 |
Carboxylic Acids/*pharmacology | 2 | 50.0 |
In Vitro | 73 | 1.0 |
Protein Subunits | 4 | 1.0 |
Recombinant Proteins | 6 | 0.0 |
Stereoisomerism | 19 | 4.0 |
Xenopus laevis | 6 | 1.0 |
Laterality/*physiology | 2 | 6.0 |
Motor Cortex/*physiology | 2 | 10.0 |
DNA Primers | 27 | 0.0 |
Mutagenesis, Site-Directed | 35 | 1.0 |
Chromatography, Affinity | 30 | 3.0 |
Peptides/*immunology | 3 | 4.0 |
Action Potentials/physiology | 2 | 4.0 |
Electric Stimulation | 8 | 3.0 |
Muscle, Skeletal/*physiology | 2 | 2.0 |
Crystallography, X-Ray | 42 | 5.0 |
Mutagenesis | 3 | 0.0 |
Protein Structure, Secondary | 17 | 1.0 |
Cervical Vertebrae/pathology/*surgery | 2 | 100.0 |
Spinal Fusion | 2 | 20.0 |
Alternative Splicing | 9 | 0.0 |
Chromosome Mapping | 50 | 0.0 |
Cloning, Molecular | 81 | 0.0 |
RNA, Messenger/genetics | 29 | 1.0 |
Sequence Homology | 4 | 1.0 |
*Ubiquitin-Protein Ligases | 5 | 0.0 |
Protein Kinase C/antagonists & inhibitors/*metabolism | 2 | 2.0 |
Signal Transduction/*physiology | 6 | 0.0 |
Sphingosine/*analogs & derivatives/pharmacology | 8 | 27.0 |
Imaging, Three-Dimensional | 5 | 18.0 |
*Membranes, Artificial | 3 | 3.0 |
Microscopy, Electron | 18 | 0.0 |
*Neoplasm Proteins | 3 | 0.0 |
Disease Progression | 11 | 0.0 |
Liver/pathology | 2 | 1.0 |
Cyclosporine/administration & dosage/blood/*pharmacokinetics | 3 | 50.0 |
Drug Monitoring/*methods | 5 | 26.0 |
Immunosuppressive Agents/administration & dosage/blood/*pharmacokinetics | 2 | 25.0 |
Cell Separation | 3 | 0.0 |
Punctures | 2 | 22.0 |
Blotting, Northern/methods | 2 | 3.0 |
Culture Media | 8 | 1.0 |
DNA, Complementary | 10 | 0.0 |
Gene Expression | 29 | 0.0 |
Polymerase Chain Reaction/methods | 10 | 0.0 |
Protein Biosynthesis | 12 | 0.0 |
*Saccharomyces cerevisiae Proteins | 5 | 0.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
Genes, Bacterial | 2 | 1.0 |
Hungary | 2 | 3.0 |
Methicillin Resistance/*genetics | 2 | 18.0 |
Polymerase Chain Reaction | 61 | 0.0 |
*Alternative Splicing | 4 | 0.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
DNA, Complementary/metabolism | 8 | 0.0 |
Exons | 17 | 0.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
RNA, Messenger/metabolism | 19 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 24 | 0.0 |
Ubiquitin-Protein Ligases | 6 | 2.0 |
Feces/microbiology | 3 | 4.0 |
Light | 5 | 2.0 |
Microscopy, Electron, Scanning | 5 | 1.0 |
Molar | 2 | 10.0 |
Resin Cements/chemistry | 2 | 16.0 |
Rosaniline Dyes/diagnostic use | 2 | 25.0 |
Statistics, Nonparametric | 10 | 0.0 |
Surface Properties | 7 | 3.0 |
Thermodynamics | 12 | 3.0 |
Disease Models, Animal | 10 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Antigens, CD4/metabolism | 4 | 1.0 |
Antiviral Agents/*pharmacology | 2 | 1.0 |
Ligands | 19 | 0.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
DNA Mutational Analysis | 16 | 0.0 |
Gene Frequency | 65 | 1.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Genetic Screening | 4 | 0.0 |
Iron/*metabolism | 2 | 1.0 |
Polymorphism, Genetic/*genetics | 6 | 0.0 |
*Conditioning, Classical | 2 | 33.0 |
Cues | 3 | 15.0 |
*Transfer (Psychology) | 2 | 66.0 |
Antibodies, Monoclonal/immunology | 17 | 1.0 |
*Binding Sites, Antibody | 2 | 5.0 |
Cell Membrane/metabolism | 16 | 1.0 |
Hemophilia A/*immunology | 4 | 22.0 |
T-Lymphocytes/immunology | 8 | 0.0 |
von Willebrand Factor/metabolism | 8 | 2.0 |
Pain, Postoperative/*drug therapy | 2 | 25.0 |
Patient Satisfaction | 2 | 5.0 |
Reoperation | 7 | 5.0 |
Treatment Outcome | 49 | 1.0 |
Vascular Resistance | 4 | 7.0 |
Carbohydrate Sequence | 12 | 3.0 |
Poland | 2 | 1.0 |
HIV Infections/virology | 3 | 4.0 |
*Bone Nails | 2 | 100.0 |
*Bone Screws | 7 | 87.0 |
Cervical Vertebrae/radiography/*surgery | 2 | 100.0 |
Spinal Fusion/*methods | 3 | 75.0 |
Calcium/metabolism/pharmacology | 3 | 10.0 |
Genetic Vectors | 11 | 0.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Phosphatidylcholines/metabolism | 5 | 5.0 |
Protein Isoforms | 5 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 10 | 1.0 |
Subcellular Fractions/enzymology | 3 | 3.0 |
Surface Plasmon Resonance | 6 | 3.0 |
Binding Sites/genetics | 15 | 1.0 |
Calcium/metabolism | 26 | 1.0 |
Isoenzymes/genetics/*metabolism | 3 | 3.0 |
Micelles | 4 | 9.0 |
Phosphatidylserines/genetics/*metabolism | 2 | 100.0 |
Protein Binding/genetics | 6 | 2.0 |
Protein Kinase C/genetics/*metabolism | 4 | 13.0 |
Protein Structure, Tertiary/genetics | 9 | 3.0 |
Protein Transport/genetics | 2 | 5.0 |
Cell Membrane/*metabolism | 9 | 3.0 |
Culture Techniques | 6 | 1.0 |
Genes, Reporter | 4 | 0.0 |
Microscopy, Confocal | 9 | 0.0 |
PC12 Cells | 2 | 0.0 |
Protein Transport | 6 | 0.0 |
Amino Acid Substitution | 14 | 1.0 |
Factor VIII/*chemistry/*metabolism | 2 | 66.0 |
Mammals | 5 | 1.0 |
von Willebrand Factor/*metabolism | 5 | 1.0 |
Administration, Inhalation | 5 | 3.0 |
Analysis of Variance | 17 | 0.0 |
Asian Continental Ancestry Group | 6 | 2.0 |
Europe/ethnology | 3 | 3.0 |
European Continental Ancestry Group | 10 | 1.0 |
Reference Values | 47 | 1.0 |
Reflex/*drug effects | 3 | 33.0 |
Sex Factors | 16 | 1.0 |
Collectins | 13 | 15.0 |
Complement 4b/metabolism | 4 | 16.0 |
*Complement Activation | 88 | 22.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 5 | 3.0 |
Biopsy | 8 | 0.0 |
Immunoenzyme Techniques | 11 | 0.0 |
Immunoglobulin G/immunology | 11 | 3.0 |
Immunoglobulin M/immunology | 4 | 3.0 |
Skin Tests | 4 | 2.0 |
Isoenzymes/chemistry/metabolism | 2 | 7.0 |
Liver/*enzymology | 6 | 1.0 |
Pliability | 2 | 9.0 |
Substrate Specificity | 33 | 1.0 |
Chi-Square Distribution | 6 | 0.0 |
Cytochrome P-450 CYP1A1/*genetics | 3 | 1.0 |
Cytochrome P-450 CYP2E1/*genetics | 10 | 8.0 |
Glutathione Transferase/*genetics | 2 | 0.0 |
Smoking | 3 | 0.0 |
Antibodies, Monoclonal/*immunology | 11 | 1.0 |
Binding Sites, Antibody | 12 | 3.0 |
DNA | 10 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 4 | 1.0 |
Epitopes/chemistry/*immunology | 3 | 15.0 |
*Polymorphism, Genetic | 44 | 0.0 |
Variation (Genetics) | 26 | 1.0 |
Base Sequence/physiology | 2 | 28.0 |
Software | 7 | 2.0 |
CD4 Lymphocyte Count | 6 | 0.0 |
CD8-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Cohort Studies | 15 | 0.0 |
HIV-1/*immunology | 10 | 2.0 |
Immunophenotyping | 4 | 0.0 |
Genetic Markers | 12 | 0.0 |
HLA Antigens/*genetics | 55 | 6.0 |
Point Mutation/genetics | 2 | 0.0 |
3T3 Cells | 4 | 0.0 |
Phosphatidylinositols/*metabolism | 2 | 2.0 |
Protein Isoforms/chemistry/metabolism | 2 | 7.0 |
Age Factors | 26 | 1.0 |
Cross-Sectional Studies | 3 | 0.0 |
Incidence | 15 | 1.0 |
Massachusetts | 2 | 11.0 |
Complement/*analysis | 44 | 25.0 |
Glomerulonephritis/complications/*immunology/pathology | 2 | 66.0 |
Precipitation | 7 | 4.0 |
Cytarabine/pharmacology | 2 | 4.0 |
Enzyme Inhibitors/pharmacology | 11 | 0.0 |
*Signal Transduction | 7 | 0.0 |
Sphingomyelins/metabolism | 2 | 6.0 |
Sphingosine/*analogs & derivatives/metabolism/pharmacology | 2 | 50.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Chick Embryo | 4 | 0.0 |
Gene Library | 11 | 0.0 |
HIV-1/*metabolism | 3 | 1.0 |
Complement 1q/immunology | 4 | 26.0 |
Complement 3/*immunology | 3 | 4.0 |
Complement 4/immunology | 12 | 30.0 |
Complement Activation/*immunology | 7 | 13.0 |
Mice, Inbred C57BL | 13 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Models, Immunological | 3 | 1.0 |
Biomechanics | 17 | 14.0 |
Computer Graphics | 3 | 5.0 |
Image Enhancement | 2 | 14.0 |
Image Processing, Computer-Assisted | 8 | 2.0 |
Range of Motion, Articular/*physiology | 3 | 75.0 |
Antigen Presentation | 3 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Free Radicals/metabolism | 2 | 3.0 |
Ions | 2 | 2.0 |
Models, Chemical | 3 | 0.0 |
Catalysis | 14 | 1.0 |
Complement Activation | 37 | 12.0 |
Autoradiography | 6 | 1.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
*Insulin Resistance | 2 | 1.0 |
*Thiazolidinediones | 2 | 2.0 |
Mexico | 2 | 2.0 |
United States | 6 | 0.0 |
HIV Antibodies/*immunology | 4 | 4.0 |
HIV Infections/immunology/virology | 2 | 7.0 |
HIV-1/genetics/*immunology | 2 | 2.0 |
*Mutation | 11 | 0.0 |
Neutralization Tests | 19 | 4.0 |
Infant, Newborn | 31 | 0.0 |
Weight Gain | 2 | 3.0 |
Bone Screws | 6 | 100.0 |
Bone Wires | 3 | 75.0 |
Fracture Fixation, Internal/*methods | 5 | 100.0 |
Retrospective Studies | 60 | 1.0 |
Tomography, X-Ray Computed/methods | 4 | 44.0 |
Carbon Isotopes | 6 | 10.0 |
Cytosol/enzymology | 7 | 3.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Mitochondria/enzymology | 3 | 2.0 |
Purines/chemistry/metabolism | 2 | 66.0 |
Amino Acid Sequence/genetics | 3 | 1.0 |
Electrochemistry | 8 | 9.0 |
Isomerism | 6 | 2.0 |
Molecular Weight | 55 | 1.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
Disaccharides/pharmacology | 2 | 25.0 |
Drug Interactions | 3 | 0.0 |
Platelet Aggregation/drug effects | 4 | 1.0 |
Fibroblasts | 6 | 1.0 |
Mass Fragmentography | 8 | 3.0 |
Gene Expression Regulation | 11 | 0.0 |
Organ Specificity | 10 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
Insulin-Like Growth Factor I/*metabolism | 2 | 1.0 |
Muscles/*cytology | 3 | 11.0 |
Myogenin/*metabolism | 2 | 40.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Complement 2/deficiency/genetics | 4 | 80.0 |
Complement 4/deficiency/genetics | 3 | 60.0 |
*Major Histocompatibility Complex | 46 | 15.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Carrier Proteins/*metabolism | 5 | 0.0 |
Complement 7/*deficiency | 2 | 40.0 |
*Chromosome Aberrations | 3 | 0.0 |
Chromosome Deletion | 7 | 1.0 |
Karyotyping | 5 | 0.0 |
Kidney Neoplasms/*genetics/pathology | 2 | 2.0 |
Multivariate Analysis | 7 | 0.0 |
Atlanto-Axial Joint/*surgery | 2 | 100.0 |
*Stereotaxic Techniques | 2 | 28.0 |
Virion/chemistry/genetics/metabolism | 2 | 66.0 |
Virus Replication | 8 | 0.0 |
Binding Sites/physiology | 2 | 1.0 |
Drug Stability | 7 | 3.0 |
Hydrogen-Ion Concentration | 49 | 3.0 |
Fatty Acids/chemistry | 2 | 40.0 |
Intestine, Small/metabolism | 2 | 3.0 |
Cervical Vertebrae/*injuries | 2 | 66.0 |
Carbon Dioxide/metabolism | 3 | 9.0 |
Fatty Acids/*metabolism | 2 | 2.0 |
Glucose/metabolism | 5 | 2.0 |
Octanoic Acids/metabolism | 2 | 100.0 |
Heat | 17 | 3.0 |
Osmolar Concentration | 11 | 1.0 |
Phosphatidylglycerols/metabolism | 2 | 40.0 |
Phosphatidylserines/*metabolism | 4 | 22.0 |
Protein Denaturation | 6 | 2.0 |
Protein Structure, Secondary/genetics | 2 | 11.0 |
Infusions, Intravenous | 9 | 1.0 |
Immunosuppressive Agents/*administration & dosage | 2 | 6.0 |
Monitoring, Immunologic/*methods | 2 | 40.0 |
Organ Transplantation | 2 | 16.0 |
Blood Coagulation Tests | 3 | 1.0 |
Epitope Mapping/*methods | 2 | 14.0 |
Hemorrhage/etiology | 2 | 9.0 |
Membranes, Artificial | 3 | 3.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Epithelium/metabolism | 4 | 1.0 |
*Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 5 | 20.0 |
*Heterogeneous-Nuclear Ribonucleoprotein Group C | 10 | 90.0 |
Heterogeneous-Nuclear Ribonucleoproteins | 18 | 15.0 |
Liver/*metabolism | 3 | 0.0 |
Anastomosis, Surgical/methods | 2 | 50.0 |
Neoplasm Recurrence, Local | 15 | 3.0 |
Postoperative Complications | 9 | 6.0 |
Rectal Neoplasms/mortality/*surgery | 2 | 100.0 |
Survival Rate | 22 | 1.0 |
Postoperative Complications/prevention & control | 2 | 6.0 |
Viral Load | 3 | 0.0 |
B-Lymphocytes/immunology | 9 | 1.0 |
*Cardiovascular Physiology | 2 | 7.0 |
Risk Factors | 34 | 0.0 |
Sex Characteristics | 5 | 0.0 |
Triglycerides/blood | 6 | 0.0 |
Cytosol/metabolism | 7 | 1.0 |
Microinjections | 2 | 0.0 |
Neutrophils/*metabolism | 3 | 1.0 |
Peptide Fragments/chemistry | 8 | 4.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 4 | 1.0 |
Trypsin | 7 | 4.0 |
Cough/*physiopathology | 3 | 75.0 |
Alanine Transaminase/blood | 2 | 1.0 |
Aldehyde Dehydrogenase/*genetics | 5 | 2.0 |
Homozygote | 42 | 2.0 |
Japan | 13 | 0.0 |
*Polymorphism, Restriction Fragment Length | 15 | 1.0 |
Polymorphism, Single-Stranded Conformational | 6 | 0.0 |
gamma-Glutamyltransferase/blood | 2 | 4.0 |
Genes, Dominant | 7 | 0.0 |
Phosphates/metabolism | 2 | 2.0 |
Phosphorylation/drug effects | 5 | 0.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 2 | 2.0 |
Signal Transduction/physiology | 4 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 5 | 0.0 |
Energy Metabolism/physiology | 2 | 3.0 |
Glutamine/metabolism | 4 | 16.0 |
Models, Theoretical | 4 | 3.0 |
Neurotransmitters/*metabolism | 2 | 6.0 |
*Blood Pressure | 3 | 2.0 |
Body Height | 5 | 3.0 |
Diastole | 2 | 2.0 |
Systole | 2 | 2.0 |
Gene Expression Regulation, Developmental | 4 | 0.0 |
Multigene Family/*genetics | 2 | 1.0 |
RNA, Messenger/genetics/metabolism | 12 | 0.0 |
*Receptors, Cell Surface | 2 | 0.0 |
Electric Stimulation/methods | 2 | 7.0 |
NAD/metabolism | 3 | 4.0 |
*Protein Conformation | 8 | 3.0 |
Sequence Homology, Nucleic Acid | 30 | 1.0 |
Disulfides/metabolism | 2 | 5.0 |
NIH 3T3 Cells | 2 | 0.0 |
Iron/metabolism | 4 | 3.0 |
DNA, Complementary/genetics | 10 | 0.0 |
Macrophages/metabolism | 5 | 1.0 |
Transcription, Genetic | 23 | 0.0 |
Recombinant Proteins/isolation & purification/metabolism | 3 | 2.0 |
Animals, Newborn | 6 | 1.0 |
Glutathione Transferase/metabolism | 7 | 0.0 |
Peptides/chemistry | 8 | 2.0 |
Protein Kinase C/*chemistry | 2 | 66.0 |
Rats, Sprague-Dawley | 19 | 0.0 |
Signal Transduction | 13 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 6 | 0.0 |
Body Weight | 4 | 0.0 |
Tomography, X-Ray Computed/*methods | 3 | 12.0 |
Cross-Over Studies | 3 | 0.0 |
Double-Blind Method | 8 | 0.0 |
Prothrombin Time | 3 | 2.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Glutamic Acid/*metabolism | 2 | 8.0 |
Glutamine/*metabolism | 2 | 25.0 |
*Magnetic Resonance Spectroscopy | 2 | 4.0 |
Synaptic Transmission/physiology | 2 | 5.0 |
African Continental Ancestry Group/genetics | 4 | 1.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
Epidemiologic Methods | 2 | 3.0 |
European Continental Ancestry Group/genetics | 7 | 1.0 |
Haplotypes/genetics | 6 | 1.0 |
Calcium-Binding Proteins/*chemistry | 2 | 11.0 |
Cell Survival/drug effects | 12 | 1.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
DNA Primers/chemistry | 9 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 5 | 0.0 |
Hela Cells/metabolism | 3 | 1.0 |
Muscle, Skeletal/*metabolism | 4 | 2.0 |
MyoD Protein/genetics/metabolism | 2 | 16.0 |
Myogenin/genetics/metabolism | 2 | 50.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Promoter Regions (Genetics) | 16 | 0.0 |
RNA, Messenger/analysis | 11 | 0.0 |
Chemotherapy, Adjuvant | 5 | 2.0 |
Drug Administration Schedule | 18 | 2.0 |
Survival Analysis | 16 | 0.0 |
Blood Glucose/metabolism | 5 | 0.0 |
Glomerular Filtration Rate | 2 | 1.0 |
Kidney/*metabolism | 2 | 1.0 |
Cytoskeleton/*metabolism | 2 | 1.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins/genetics/metabolism | 2 | 1.0 |
Quail | 2 | 4.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 2 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 6 | 0.0 |
Vanadates/pharmacology | 2 | 1.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Electrophysiology | 6 | 1.0 |
Gene Deletion | 9 | 0.0 |
Oocytes/metabolism | 2 | 1.0 |
Rats, Inbred F344 | 6 | 1.0 |
Xenopus | 6 | 1.0 |
Antigens, CD4/*metabolism | 2 | 0.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
HIV-1/immunology | 2 | 2.0 |
Peptide Fragments/chemistry/genetics/metabolism | 4 | 5.0 |
Receptors, Chemokine/*metabolism | 2 | 1.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
HIV Envelope Protein gp120/genetics/*metabolism | 3 | 8.0 |
Immunoglobulin G/metabolism | 5 | 2.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology | 2 | 2.0 |
Receptors, Melatonin | 2 | 12.0 |
Immunoglobulin G/blood | 6 | 2.0 |
Neutrophils/immunology | 5 | 2.0 |
Phagocytosis/immunology | 2 | 3.0 |
Cervical Vertebrae/*physiopathology/radiography | 2 | 100.0 |
Complement 2/immunology | 10 | 90.0 |
Complement 3/immunology | 11 | 15.0 |
Heating | 2 | 9.0 |
Lupus Erythematosus, Systemic/blood/*immunology | 2 | 5.0 |
Staphylococcus aureus/immunology | 3 | 2.0 |
Streptococcus pneumoniae/immunology | 2 | 9.0 |
Biological Markers/analysis | 2 | 0.0 |
Prognosis | 39 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Introns | 6 | 0.0 |
Myocardium/metabolism | 3 | 1.0 |
Testis/metabolism | 2 | 0.0 |
Antigens, CD4/physiology | 2 | 2.0 |
HIV-1/*genetics/immunology | 2 | 8.0 |
Mast-Cell Sarcoma/enzymology | 2 | 100.0 |
Organ Specificity/genetics | 5 | 3.0 |
Antibodies, Viral/immunology | 3 | 3.0 |
Convalescence | 2 | 6.0 |
Germany | 5 | 1.0 |
Immune Sera/immunology | 5 | 2.0 |
Viral Proteins/*immunology | 2 | 5.0 |
Fibrinogen/metabolism | 5 | 2.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
Sterilization | 2 | 28.0 |
Tumor Markers, Biological | 2 | 0.0 |
Consensus Sequence | 5 | 0.0 |
Mice, Inbred Strains | 7 | 0.0 |
Administration, Cutaneous | 2 | 2.0 |
Biotransformation | 4 | 0.0 |
DNA/analysis | 9 | 1.0 |
Polymorphism, Restriction Fragment Length | 20 | 0.0 |
Immunoglobulin M/blood | 5 | 3.0 |
Virus Cultivation | 2 | 4.0 |
Aspartic Acid/chemistry | 2 | 6.0 |
Electrostatics | 4 | 2.0 |
Caco-2 Cells | 3 | 0.0 |
Cell Differentiation/drug effects | 7 | 0.0 |
Cell Membrane/physiology | 2 | 1.0 |
Interferon Type II/*pharmacology | 8 | 1.0 |
Sodium/metabolism | 3 | 2.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
Cell Count | 3 | 0.0 |
Blood Pressure/*physiology | 2 | 2.0 |
Escherichia coli/genetics | 6 | 1.0 |
Carcinoma, Hepatocellular/*pathology | 2 | 4.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Injections, Subcutaneous | 2 | 0.0 |
Lymphatic Metastasis | 10 | 0.0 |
*Neoplasm Metastasis | 2 | 2.0 |
Immunosuppression | 2 | 1.0 |
Italy/epidemiology | 5 | 2.0 |
Antiviral Agents/*chemical synthesis/chemistry/pharmacology | 3 | 50.0 |
HIV-1/drug effects | 3 | 7.0 |
Herpesvirus 1, Human/drug effects | 2 | 40.0 |
Antineoplastic Agents/*chemical synthesis/chemistry/pharmacology | 2 | 7.0 |
DNA/*chemistry | 2 | 3.0 |
Electrophoresis, Agar Gel | 16 | 3.0 |
Materials Testing | 2 | 2.0 |
Stress, Mechanical | 4 | 1.0 |
Blood Proteins/genetics | 2 | 3.0 |
Complement/*genetics | 35 | 60.0 |
Ethnic Groups/genetics | 2 | 1.0 |
Genes, Structural | 17 | 1.0 |
Butyrates/pharmacology | 2 | 5.0 |
Sodium/*metabolism | 3 | 4.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
*Alleles | 21 | 1.0 |
Haplotypes | 33 | 1.0 |
Pan troglodytes | 4 | 3.0 |
Phosphatidylinositols/metabolism | 3 | 2.0 |
*Drug Monitoring | 3 | 15.0 |
Brazil/epidemiology | 3 | 3.0 |
Environment | 5 | 5.0 |
Nutritional Status | 2 | 1.0 |
Mice, Mutant Strains | 3 | 0.0 |
*Cervical Vertebrae | 3 | 27.0 |
Italy | 6 | 0.0 |
ROC Curve | 4 | 2.0 |
Complement 2/*deficiency | 56 | 100.0 |
Immunoglobulin G/*immunology | 7 | 7.0 |
Pneumococcal Infections/*immunology | 4 | 40.0 |
Septicemia/*immunology | 3 | 42.0 |
Blotting, Southern | 18 | 0.0 |
Carps/*genetics | 2 | 28.0 |
Cytochrome P-450 Enzyme System/*genetics | 9 | 2.0 |
Oceanic Ancestry Group/*genetics | 2 | 8.0 |
Computer Simulation | 7 | 2.0 |
Isoantibodies/*blood | 2 | 10.0 |
Cervical Vertebrae/*radiography | 5 | 71.0 |
Prostatic Neoplasms/*pathology | 3 | 2.0 |
Radial Artery/*physiology | 2 | 66.0 |
Leukemia/genetics | 2 | 4.0 |
Complement 2/genetics | 36 | 73.0 |
Complement Pathway, Classical/genetics | 2 | 28.0 |
Gene Expression Regulation/immunology | 3 | 1.0 |
HLA-DR Antigens/genetics | 14 | 3.0 |
Macaca mulatta | 6 | 1.0 |
Peptide Fragments/genetics/metabolism | 2 | 1.0 |
Alternative Splicing/*genetics | 2 | 1.0 |
Endoplasmic Reticulum/*metabolism | 2 | 1.0 |
Nerve Tissue Proteins/metabolism | 3 | 1.0 |
*Carrier Proteins | 7 | 1.0 |
Endosomes/*metabolism | 4 | 3.0 |
rab GTP-Binding Proteins/*metabolism | 2 | 7.0 |
Magnetic Resonance Spectroscopy/methods | 6 | 13.0 |
*Nucleic Acid Conformation | 2 | 2.0 |
Temperature | 7 | 0.0 |
*Conserved Sequence | 3 | 2.0 |
HIV Envelope Protein gp120/*chemistry/genetics | 2 | 50.0 |
Viral Envelope Proteins/*chemistry/genetics | 2 | 100.0 |
CHO Cells | 8 | 0.0 |
Antigen-Antibody Complex/*blood | 2 | 3.0 |
Autoantibodies/*immunology | 9 | 3.0 |
Epitopes/immunology | 12 | 2.0 |
Cell Line, Transformed | 6 | 0.0 |
Peptide Fragments/genetics/*metabolism | 2 | 7.0 |
Amino Acids | 2 | 6.0 |
Codon | 2 | 0.0 |
HIV-1/*genetics | 4 | 1.0 |
*Variation (Genetics) | 21 | 2.0 |
Apoptosis/*drug effects | 4 | 0.0 |
Ceramides/*pharmacology | 6 | 30.0 |
Deoxyglucose/metabolism | 2 | 15.0 |
Monosaccharide Transport Proteins/*metabolism | 2 | 7.0 |
Neutrophils/*drug effects/metabolism | 3 | 6.0 |
Sphingomyelin Phosphodiesterase/pharmacology | 3 | 18.0 |
Tetrazolium Salts/metabolism | 2 | 12.0 |
Plasmids/metabolism | 4 | 0.0 |
*Magnetic Resonance Imaging | 5 | 3.0 |
Apolipoproteins E/*genetics | 3 | 0.0 |
Family Health | 6 | 0.0 |
Odds Ratio | 4 | 0.0 |
Antigens/immunology | 2 | 1.0 |
Factor VIII/*chemistry/genetics/*immunology | 2 | 100.0 |
Hemophilia A/blood/immunology | 2 | 50.0 |
Dinoprostone/metabolism | 2 | 2.0 |
Macrophage Activation/drug effects | 3 | 5.0 |
Peroxidase/metabolism | 3 | 2.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Zymosan/pharmacology | 8 | 8.0 |
Blood Coagulation | 4 | 2.0 |
*Models, Molecular | 4 | 3.0 |
Cattle | 34 | 1.0 |
*ADP Ribose Transferases | 2 | 2.0 |
Actins/metabolism | 4 | 0.0 |
Bacterial Toxins/*pharmacology | 2 | 6.0 |
Biopolymers | 2 | 1.0 |
Botulinum Toxins/pharmacology | 2 | 11.0 |
Spain | 7 | 2.0 |
Immunoassay | 8 | 3.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Decarboxylation | 2 | 40.0 |
Hydrogen Bonding | 8 | 4.0 |
Protein Folding | 4 | 0.0 |
Sequence Deletion | 11 | 0.0 |
Substrate Specificity/genetics | 2 | 4.0 |
Observer Variation | 5 | 4.0 |
Sequence Analysis | 6 | 1.0 |
Cell Nucleus/*ultrastructure | 2 | 10.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 2 | 1.0 |
Liposomes/*pharmacology | 2 | 22.0 |
Mice, Inbred C3H | 5 | 0.0 |
Arachidonic Acid/metabolism | 3 | 3.0 |
Carrier Proteins/metabolism | 5 | 0.0 |
Membrane Proteins/metabolism | 8 | 1.0 |
Nuclear Envelope/enzymology | 2 | 50.0 |
Vimentin/metabolism | 2 | 1.0 |
Ribonucleoproteins/*metabolism | 4 | 9.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Epitopes/metabolism | 3 | 5.0 |
Immunoglobulin G | 10 | 8.0 |
Protein Binding/physiology | 2 | 0.0 |
X-Ray Diffraction | 12 | 14.0 |
Cholesterol/*metabolism | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 4 | 0.0 |
Mitochondria/metabolism | 2 | 0.0 |
Phosphoproteins/genetics/*metabolism | 2 | 1.0 |
Tyrosine/metabolism | 6 | 0.0 |
Adenylate Cyclase/*antagonists & inhibitors | 2 | 25.0 |
Cyclic AMP/metabolism | 5 | 0.0 |
Cyclic GMP/metabolism | 3 | 3.0 |
Dimerization | 8 | 0.0 |
Isoenzymes/*antagonists & inhibitors | 2 | 6.0 |
*Complement | 16 | 25.0 |
Calcimycin/pharmacology | 3 | 1.0 |
Green Fluorescent Proteins | 4 | 0.0 |
Glycoside Hydrolases/metabolism | 2 | 6.0 |
Epitopes, T-Lymphocyte/immunology | 2 | 2.0 |
Peptide Fragments/immunology/metabolism | 2 | 4.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Neurons/*metabolism | 4 | 1.0 |
Calcium Signaling/*physiology | 2 | 4.0 |
Estrogens/pharmacology | 2 | 2.0 |
Pedigree | 93 | 1.0 |
Fourier Analysis | 4 | 7.0 |
*Heart Valve Prosthesis | 3 | 15.0 |
DNA/*metabolism | 5 | 1.0 |
Adenocarcinoma/*radiotherapy/surgery | 4 | 100.0 |
Cause of Death | 3 | 1.0 |
Colonic Neoplasms/*radiotherapy/surgery | 3 | 100.0 |
Intestinal Obstruction/etiology | 2 | 40.0 |
Longitudinal Studies | 9 | 1.0 |
Neoplasm Recurrence, Local/pathology | 2 | 3.0 |
Neoplasm Staging | 45 | 1.0 |
Pilot Projects | 6 | 0.0 |
Radiotherapy, Adjuvant | 8 | 9.0 |
Binding, Competitive/immunology | 2 | 2.0 |
Complement 1 Inactivators/metabolism | 7 | 43.0 |
Complement Activation/immunology | 2 | 6.0 |
Dose-Response Relationship, Immunologic | 20 | 3.0 |
Molecular Mimicry | 3 | 4.0 |
Mycophenolic Acid/*analogs & derivatives/blood/therapeutic use | 2 | 100.0 |
Cyclosporine/*administration & dosage/blood | 3 | 100.0 |
Immunosuppressive Agents/*administration & dosage/blood | 3 | 75.0 |
*Liver Transplantation | 5 | 3.0 |
Cholesterol/metabolism | 2 | 0.0 |
Liver/metabolism | 7 | 0.0 |
Epitopes | 14 | 1.0 |
Factor VIII/*immunology/therapeutic use | 4 | 57.0 |
Histidine/*chemistry | 3 | 27.0 |
Prions/*chemistry | 2 | 33.0 |
*Muscle Proteins | 2 | 0.0 |
*Protein Biosynthesis | 6 | 1.0 |
RNA, Messenger/*genetics | 5 | 1.0 |
Fatty Acids, Volatile/*metabolism | 2 | 100.0 |
Linear Models | 6 | 1.0 |
Probability | 3 | 0.0 |
Acetylation | 2 | 0.0 |
Ceramides/metabolism | 3 | 8.0 |
Genes, MHC Class II/*genetics | 2 | 2.0 |
Immunogenetics | 4 | 8.0 |
Spinal Cord Injuries/*physiopathology | 3 | 37.0 |
HIV Envelope Protein gp120/*immunology | 5 | 4.0 |
HIV Envelope Protein gp41/*immunology | 2 | 9.0 |
Leukocytes, Mononuclear/virology | 4 | 3.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Biological Assay | 6 | 2.0 |
Growth Inhibitors/pharmacology | 2 | 1.0 |
Proteins/*metabolism | 3 | 0.0 |
Sphingomyelin Phosphodiesterase/*pharmacology | 2 | 100.0 |
Microcirculation | 2 | 0.0 |
Umbilical Veins | 3 | 0.0 |
Carotid Artery, Internal/*surgery | 2 | 100.0 |
Membrane Proteins/*metabolism | 3 | 0.0 |
Ubiquitins/*metabolism | 2 | 1.0 |
Cysteine Endopeptidases/*metabolism | 4 | 1.0 |
Benzimidazoles/*chemical synthesis/chemistry/pharmacology | 3 | 75.0 |
Fibroblasts/drug effects | 3 | 3.0 |
Plaque Assay | 4 | 5.0 |
Skin/cytology | 2 | 1.0 |
Cell Compartmentation | 2 | 0.0 |
Graft Rejection/epidemiology | 5 | 22.0 |
Treatment Failure | 5 | 1.0 |
AIDS Vaccines/*immunology | 3 | 10.0 |
Gene Products, env/*immunology | 2 | 8.0 |
Immunization | 7 | 1.0 |
Mice, Inbred BALB C | 14 | 0.0 |
Recombinant Fusion Proteins/*immunology | 2 | 9.0 |
Vaccines, Synthetic/*immunology | 2 | 7.0 |
Hemodynamic Processes/*drug effects | 2 | 1.0 |
Single-Blind Method | 2 | 0.0 |
Evaluation Studies | 15 | 2.0 |
Cell Survival | 7 | 0.0 |
Embryonic and Fetal Development | 3 | 0.0 |
Heterogeneous-Nuclear Ribonucleoprotein Group C | 8 | 80.0 |
Epidermal Growth Factor/metabolism/pharmacology | 2 | 3.0 |
Phosphatidylinositol Phosphates/metabolism | 2 | 4.0 |
Phosphotyrosine/metabolism | 4 | 0.0 |
Platelet-Derived Growth Factor/metabolism | 2 | 3.0 |
Cell Adhesion | 4 | 0.0 |
Complement 2/biosynthesis/genetics | 5 | 100.0 |
Complement 3/biosynthesis/genetics | 2 | 66.0 |
Cost-Benefit Analysis | 2 | 1.0 |
Risk | 8 | 0.0 |
*Epidemiology, Molecular | 3 | 17.0 |
Measles/*epidemiology/virology | 2 | 100.0 |
Measles virus/classification/*genetics | 2 | 100.0 |
Nucleoproteins/genetics | 2 | 50.0 |
*Medicine, Chinese Traditional | 2 | 8.0 |
*Pulse | 2 | 13.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
*Area Under Curve | 4 | 80.0 |
Immunosuppressive Agents/*pharmacokinetics | 8 | 47.0 |
Crystallography, X-Ray/methods | 7 | 30.0 |
Placenta/*enzymology | 2 | 2.0 |
Recombinant Proteins/chemistry/isolation & purification | 2 | 14.0 |
Lectins/chemistry | 2 | 18.0 |
Solutions | 7 | 3.0 |
Spectrum Analysis, Mass/instrumentation/*methods | 2 | 25.0 |
Factor Analysis, Statistical | 2 | 5.0 |
*Models, Genetic | 5 | 4.0 |
Complement Activation/*drug effects | 20 | 21.0 |
Heparin/*pharmacology | 2 | 1.0 |
DNA Primers/genetics | 8 | 0.0 |
*Apoptosis | 8 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Sheep | 30 | 5.0 |
Nuclear Magnetic Resonance, Biomolecular | 5 | 3.0 |
Spectrophotometry, Infrared | 4 | 18.0 |
Reference Standards | 5 | 2.0 |
Calcium/physiology | 4 | 1.0 |
Lymph Nodes/pathology/radiation effects | 2 | 100.0 |
Cell Cycle/*drug effects | 2 | 1.0 |
Cytokines/pharmacology | 4 | 1.0 |
Family | 3 | 0.0 |
France | 5 | 1.0 |
*Linkage Disequilibrium | 2 | 1.0 |
Major Histocompatibility Complex/*genetics | 12 | 7.0 |
Agrin/pharmacology/*physiology | 2 | 100.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
Dystroglycans | 4 | 8.0 |
Muscle Proteins/*physiology | 2 | 20.0 |
Protein Processing, Post-Translational | 6 | 0.0 |
Exercise/*physiology | 2 | 0.0 |
Physical Fitness/physiology | 2 | 16.0 |
Running/*physiology | 2 | 5.0 |
Glutathione/pharmacology | 2 | 5.0 |
Ultraviolet Rays/*adverse effects | 2 | 4.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Lectins/*immunology | 4 | 14.0 |
Homeostasis | 2 | 0.0 |
Hemophilia A/blood/*genetics | 3 | 50.0 |
*Mutation, Missense | 3 | 0.0 |
N-Formylmethionine Leucyl-Phenylalanine/*pharmacology | 2 | 4.0 |
Sphingosine/analogs & derivatives/pharmacology | 4 | 26.0 |
Superoxides/*metabolism | 2 | 2.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 4 | 0.0 |
Antihypertensive Agents/adverse effects | 2 | 50.0 |
Hematocrit | 3 | 0.0 |
*Hemodilution | 2 | 40.0 |
Cell Differentiation/*drug effects | 4 | 2.0 |
HL-60 Cells | 4 | 0.0 |
Molecular Conformation | 16 | 7.0 |
Agrin/*physiology | 2 | 28.0 |
*Plant Lectins | 6 | 5.0 |
Pregnancy Complications, Cardiovascular/*drug therapy | 2 | 66.0 |
Acute Disease | 10 | 0.0 |
*Heart Transplantation | 2 | 2.0 |
Postoperative Complications/mortality | 2 | 28.0 |
Stroke Volume | 2 | 3.0 |
Cross Reactions | 15 | 1.0 |
Factor Xa/metabolism | 2 | 3.0 |
Swine | 21 | 1.0 |
Thrombin/metabolism | 3 | 2.0 |
Immunoglobulin Variable Region/genetics | 2 | 1.0 |
Peptide Library | 2 | 1.0 |
Arachidonic Acid/*metabolism | 2 | 5.0 |
Kidney | 4 | 1.0 |
Phospholipases A/*chemistry/*metabolism | 2 | 100.0 |
Pressure | 3 | 2.0 |
Antibodies/analysis | 4 | 3.0 |
*Cold | 2 | 3.0 |
Complement/analysis | 14 | 10.0 |
Glutamates/pharmacology | 2 | 22.0 |
Immunoglobulins/analysis | 12 | 4.0 |
Immunosorbent Techniques | 7 | 2.0 |
Phenylalanine/*metabolism | 2 | 9.0 |
Protons | 5 | 5.0 |
Carrier Proteins/*physiology | 3 | 1.0 |
Complement 3 Convertase/metabolism | 10 | 25.0 |
*Complement Pathway, Classical | 44 | 50.0 |
Polysaccharides, Bacterial/*immunology | 3 | 12.0 |
Serotyping | 9 | 4.0 |
Equipment Design | 7 | 5.0 |
Complement/*immunology | 13 | 9.0 |
Complement 1/immunology | 7 | 43.0 |
Complement Inactivators/*pharmacology | 5 | 19.0 |
Erythrocytes/drug effects | 2 | 9.0 |
Hemolysis/*drug effects | 3 | 7.0 |
Factor Va/*chemistry/metabolism | 2 | 100.0 |
Alanine/genetics | 2 | 1.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
Factor Xa/chemistry/*metabolism | 2 | 33.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 4 | 1.0 |
Cell-Free System | 4 | 1.0 |
HIV Envelope Protein gp120/*genetics | 4 | 16.0 |
Models, Genetic | 9 | 0.0 |
Nucleic Acid Conformation | 5 | 0.0 |
*Recombination, Genetic | 5 | 1.0 |
Retroviridae/genetics | 2 | 0.0 |
Adhesins, Bacterial/chemistry/*isolation & purification/pharmacology | 2 | 100.0 |
Hemagglutination Tests | 6 | 7.0 |
Mannheimia haemolytica/*chemistry | 2 | 100.0 |
Jurkat Cells | 2 | 0.0 |
Lymphocyte Activation | 8 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Complement Hemolytic Activity Assay/*methods | 2 | 66.0 |
Complement Inactivators | 7 | 36.0 |
Complement Pathway, Alternative | 24 | 20.0 |
Complement Pathway, Classical | 37 | 31.0 |
Hemolysis | 63 | 20.0 |
Lupus Erythematosus, Systemic/immunology | 11 | 9.0 |
Recombinant Proteins/chemistry/isolation & purification/metabolism | 3 | 3.0 |
Antibodies, Monoclonal | 20 | 0.0 |
Carbohydrate Conformation | 3 | 2.0 |
Chromatography, Ion Exchange | 13 | 3.0 |
*Mutagenesis, Site-Directed | 2 | 2.0 |
Recombinant Proteins/biosynthesis/chemistry/isolation & purification | 2 | 6.0 |
Peptide Fragments/*metabolism | 3 | 2.0 |
RNA, Viral/blood | 2 | 0.0 |
Bone Density | 2 | 1.0 |
*Bone Wires | 2 | 100.0 |
Carcinoma/mortality/pathology/*surgery | 2 | 100.0 |
Rectal Neoplasms/mortality/pathology/*surgery | 3 | 75.0 |
Carrier Proteins/*chemistry/genetics/*metabolism | 2 | 4.0 |
Nerve Tissue Proteins/*chemistry | 2 | 5.0 |
Mutation/genetics | 2 | 0.0 |
Prealbumin/*chemistry/genetics/metabolism | 2 | 66.0 |
Chronic Disease | 18 | 1.0 |
Radioimmunoassay/methods | 2 | 1.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Kidney/pathology | 3 | 2.0 |
DNA/biosynthesis | 4 | 0.0 |
*Lasers | 2 | 9.0 |
Complement 2/*deficiency/genetics | 26 | 96.0 |
Guinea Pigs | 50 | 6.0 |
Injections, Intravenous | 8 | 1.0 |
Complement 3 Convertase/biosynthesis | 3 | 33.0 |
Complement 3b/immunology | 4 | 11.0 |
Complement 5/immunology | 4 | 23.0 |
Erythrocytes/immunology | 17 | 7.0 |
Data Interpretation, Statistical | 3 | 1.0 |
*Genes, env | 6 | 19.0 |
Calcium/*physiology | 4 | 3.0 |
Complement Pathway, Alternative/immunology | 4 | 30.0 |
Guinea Pigs/*immunology | 2 | 66.0 |
Rats/immunology | 2 | 33.0 |
Lung Neoplasms/*genetics | 3 | 1.0 |
Discriminant Analysis | 3 | 3.0 |
*Image Processing, Computer-Assisted | 2 | 4.0 |
DNA, Complementary/chemistry/genetics | 2 | 0.0 |
Europe | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 3 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1 | 3 | 2.0 |
Proteins/*physiology | 2 | 1.0 |
*Fracture Fixation, Internal | 3 | 100.0 |
Fracture Healing/physiology | 5 | 55.0 |
Postoperative Care | 12 | 16.0 |
Postoperative Complications/radiography | 2 | 50.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Proteasome Endopeptidase Complex | 12 | 2.0 |
Clonidine/*therapeutic use | 2 | 40.0 |
Body Mass Index | 3 | 0.0 |
Cholesterol/blood | 5 | 0.0 |
Caspases/metabolism | 2 | 0.0 |
Free Radicals | 3 | 1.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
Oxidative Stress | 2 | 0.0 |
Permeability | 3 | 1.0 |
Reactive Oxygen Species | 2 | 1.0 |
Cyclosporine/adverse effects/*blood/*therapeutic use | 2 | 100.0 |
Emulsions | 8 | 11.0 |
Immunosuppressive Agents/adverse effects/*blood/*therapeutic use | 2 | 100.0 |
Isotope Labeling | 2 | 2.0 |
Antisense Elements (Genetics) | 2 | 3.0 |
Ceramides/pharmacology | 2 | 6.0 |
Interleukin-1/pharmacology | 5 | 0.0 |
Lipopolysaccharides/pharmacology | 10 | 1.0 |
Nerve Tissue Proteins/*physiology | 2 | 3.0 |
C-Reactive Protein/*immunology/metabolism | 2 | 25.0 |
Brain Chemistry | 2 | 0.0 |
Gene Amplification | 4 | 0.0 |
Saccharomyces cerevisiae/genetics | 4 | 0.0 |
Cell Degranulation | 2 | 4.0 |
Recombinant Fusion Proteins/chemistry/genetics | 3 | 17.0 |
Electric Impedance | 2 | 3.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Cell Cycle | 4 | 0.0 |
Actuarial Analysis | 6 | 8.0 |
*Prostatectomy | 2 | 7.0 |
Cell Fusion | 2 | 0.0 |
Extracellular Matrix/*metabolism | 2 | 2.0 |
Integrins/metabolism | 2 | 1.0 |
Muscles/*cytology/metabolism | 3 | 30.0 |
Molecular Probes | 2 | 3.0 |
Photochemistry | 3 | 5.0 |
Caspases/*metabolism | 2 | 0.0 |
Cytochrome c Group/*metabolism | 2 | 6.0 |
Enzyme Activation/drug effects | 5 | 0.0 |
Membrane Potentials | 4 | 1.0 |
*Calcium-Binding Proteins | 4 | 8.0 |
Escherichia coli | 9 | 1.0 |
Spin Labels | 2 | 1.0 |
Gene Duplication | 3 | 1.0 |
*Linkage (Genetics) | 17 | 1.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
*Xenopus Proteins | 2 | 0.0 |
Xenopus laevis/genetics | 2 | 11.0 |
Capsaicin/diagnostic use | 2 | 100.0 |
Complement 2/*biosynthesis | 23 | 95.0 |
Complement 3/*biosynthesis | 4 | 9.0 |
Cycloheximide/pharmacology | 15 | 2.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Phosphatidic Acids/*metabolism | 2 | 22.0 |
Carrier Proteins/*genetics | 5 | 0.0 |
Complement 1/*physiology | 4 | 80.0 |
DNA, Complementary/chemistry | 4 | 2.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Mitogens/pharmacology | 2 | 0.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Anthropometry | 7 | 2.0 |
Australia | 3 | 1.0 |
Cephalometry | 4 | 14.0 |
Cervical Vertebrae/*anatomy & histology | 4 | 100.0 |
Mandible/anatomy & histology | 2 | 66.0 |
*Oceanic Ancestry Group | 2 | 11.0 |
*Cell Cycle Proteins | 2 | 0.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Muscle, Skeletal/*cytology | 4 | 25.0 |
S Phase | 3 | 0.0 |
Transcription Factors/*biosynthesis/genetics | 3 | 3.0 |
HIV Antibodies/*blood | 2 | 5.0 |
Papio | 3 | 1.0 |
Enzyme Multiplied Immunoassay Technique | 2 | 50.0 |
Kidney Transplantation | 3 | 2.0 |
Forced Expiratory Volume/physiology | 3 | 8.0 |
Neck | 12 | 19.0 |
Reflex/*physiology | 2 | 8.0 |
Automation | 2 | 3.0 |
Spectrophotometry, Ultraviolet | 11 | 6.0 |
Cytopathogenic Effect, Viral/drug effects | 3 | 13.0 |
Virus Replication/*drug effects | 2 | 1.0 |
Absorption | 3 | 2.0 |
Cyclosporine/blood/*pharmacokinetics/therapeutic use | 6 | 85.0 |
Immunosuppressive Agents/blood/*pharmacokinetics/therapeutic use | 4 | 80.0 |
Kidney Transplantation/immunology | 3 | 5.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Complement/*physiology | 8 | 9.0 |
Complement 2/deficiency/physiology | 2 | 100.0 |
Drug Synergism | 8 | 0.0 |
Immune Sera | 13 | 4.0 |
Calcium/pharmacology | 4 | 1.0 |
Exons/genetics | 3 | 0.0 |
Introns/genetics | 4 | 0.0 |
Isoenzymes/chemistry/genetics | 2 | 11.0 |
Oxygen/metabolism | 2 | 0.0 |
Spectrophotometry | 4 | 2.0 |
Macrophage Activation | 3 | 1.0 |
Phospholipases A/*metabolism | 2 | 4.0 |
Alzheimer Disease/*metabolism | 3 | 1.0 |
Brain/*metabolism | 7 | 1.0 |
Complement/genetics/*metabolism | 2 | 50.0 |
Complement Activation/*physiology | 2 | 8.0 |
Carbohydrates/metabolism | 2 | 3.0 |
Complement/deficiency/*genetics | 2 | 100.0 |
Molecular Biology | 2 | 0.0 |
*Multigene Family | 8 | 1.0 |
Bridged Compounds/pharmacology | 2 | 20.0 |
Lipopolysaccharides/*pharmacology | 5 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
*Mitogen-Activated Protein Kinases | 3 | 0.0 |
Thiones/pharmacology | 2 | 18.0 |
Breast Neoplasms | 3 | 1.0 |
Cell Cycle/drug effects/physiology | 2 | 3.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
*Cerebrovascular Circulation | 2 | 5.0 |
Oximetry/*methods | 2 | 50.0 |
Antibodies/immunology | 10 | 3.0 |
Radioimmunoassay | 11 | 0.0 |
Blood | 4 | 2.0 |
Microbial Sensitivity Tests | 4 | 1.0 |
Lumbar Vertebrae/*anatomy & histology | 2 | 100.0 |
Sex Distribution | 2 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 2 | 2.0 |
*Proto-Oncogenes | 3 | 0.0 |
Cerebral Cortex/*physiology | 3 | 7.0 |
Contingent Negative Variation/*physiology | 2 | 28.0 |
Motor Cortex/physiology | 2 | 18.0 |
Complement 3 Convertase/*genetics | 2 | 66.0 |
Linkage (Genetics) | 64 | 2.0 |
Major Histocompatibility Complex | 19 | 7.0 |
Autoimmune Diseases/immunology | 3 | 3.0 |
Calcium-Binding Proteins/*immunology | 2 | 50.0 |
Epitopes/*analysis | 6 | 3.0 |
Peptide Fragments/immunology | 4 | 1.0 |
Ribonucleoproteins/*immunology | 2 | 15.0 |
Recombinant Proteins/genetics/metabolism | 5 | 0.0 |
*Cell Cycle | 2 | 0.0 |
Calcineurin/antagonists & inhibitors | 4 | 33.0 |
Cyclosporine/administration & dosage/*pharmacokinetics | 3 | 30.0 |
DNA, Circular | 2 | 50.0 |
DNA, Single-Stranded | 2 | 2.0 |
*Genome, Viral | 2 | 2.0 |
Complement 3/*genetics | 6 | 10.0 |
Complement 4/genetics | 28 | 45.0 |
Complement Factor B/*genetics | 28 | 21.0 |
*Gene Duplication | 2 | 1.0 |
Actins/*metabolism | 3 | 1.0 |
Physical Stimulation | 2 | 4.0 |
Rats, Inbred Strains | 7 | 0.0 |
Stimulation, Chemical | 4 | 0.0 |
Photic Stimulation | 3 | 4.0 |
Reaction Time/physiology | 8 | 8.0 |
Severity of Illness Index | 7 | 0.0 |
Pain/etiology | 3 | 20.0 |
Prone Position | 2 | 40.0 |
Spinal Fusion/*instrumentation | 2 | 66.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
Oligonucleotide Probes | 8 | 1.0 |
Posture | 2 | 2.0 |
Fetal Blood/*chemistry | 3 | 5.0 |
*Ploidies | 2 | 2.0 |
Complement 4/metabolism/physiology | 2 | 66.0 |
Oncorhynchus mykiss | 2 | 12.0 |
Serine Endopeptidases/*analysis | 2 | 16.0 |
*Antigens, CD | 3 | 0.0 |
Spodoptera | 2 | 0.0 |
Base Composition | 2 | 0.0 |
*Enhancer Elements (Genetics) | 4 | 1.0 |
Nuclear Proteins/metabolism | 5 | 0.0 |
*Promoter Regions (Genetics) | 14 | 0.0 |
Repetitive Sequences, Nucleic Acid | 7 | 0.0 |
Mexico/epidemiology | 3 | 10.0 |
Polymerase Chain Reaction/*methods | 4 | 0.0 |
*Bone Plates | 2 | 100.0 |
Magnesium/metabolism | 4 | 5.0 |
Injections, Spinal | 2 | 5.0 |
Hemophilia A/blood | 2 | 12.0 |
*Protein Structure, Tertiary | 4 | 3.0 |
Recombinant Fusion Proteins/immunology | 2 | 1.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
HLA-C Antigens/*genetics | 2 | 2.0 |
Haplotypes/*genetics | 3 | 1.0 |
Histocompatibility Antigens Class I/genetics | 2 | 2.0 |
Histocompatibility Antigens Class II/genetics | 15 | 12.0 |
Drosophila/genetics | 2 | 1.0 |
Open Reading Frames | 2 | 0.0 |
Complement 2/*genetics | 41 | 89.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
Vascular Resistance/drug effects/*physiology | 2 | 66.0 |
Catheterization | 2 | 8.0 |
*Aromatase Inhibitors | 2 | 11.0 |
Placenta/enzymology | 4 | 5.0 |
Bacteria/immunology | 3 | 30.0 |
Disease Susceptibility | 12 | 1.0 |
Immunologic Deficiency Syndromes/genetics | 5 | 29.0 |
Infection/immunology | 3 | 10.0 |
Lupus Erythematosus, Systemic/genetics/immunology | 3 | 27.0 |
Oligosaccharides/metabolism | 2 | 4.0 |
*Capsid Proteins | 3 | 2.0 |
*Viral Proteins | 2 | 1.0 |
Zinc/metabolism | 2 | 2.0 |
*Bacterial Adhesion | 2 | 4.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Complement 2/metabolism | 21 | 77.0 |
Complement 3b/metabolism | 8 | 7.0 |
Complement Factor D/metabolism | 4 | 66.0 |
Conserved Sequence/*genetics | 2 | 3.0 |
Properdin/pharmacology | 2 | 50.0 |
Buffers | 9 | 7.0 |
Solvents | 2 | 3.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
*Helix-Loop-Helix Motifs | 2 | 2.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
RNA Splicing | 2 | 0.0 |
Chemistry, Pharmaceutical | 2 | 5.0 |
Neoplasm Metastasis | 12 | 1.0 |
Fetus | 3 | 0.0 |
Membrane Glycoproteins/*physiology | 2 | 0.0 |
Complement 2/deficiency/*genetics | 2 | 100.0 |
Complement 4/deficiency/*genetics | 3 | 21.0 |
Steroid 21-Hydroxylase/genetics | 7 | 16.0 |
Neurologic Examination | 7 | 6.0 |
Spinal Cord/pathology | 2 | 2.0 |
Complement Activation/physiology | 4 | 21.0 |
Complement Membrane Attack Complex/*metabolism | 3 | 14.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 3 | 3.0 |
Calibration | 3 | 2.0 |
Chromatography/*methods | 2 | 15.0 |
Adsorption | 2 | 1.0 |
Hypersensitivity/immunology | 2 | 5.0 |
Hybrid Cells | 3 | 0.0 |
*Nuclear Proteins | 8 | 0.0 |
Phosphoproteins/*genetics | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
HIV Protease Inhibitors/*chemical synthesis/chemistry | 2 | 100.0 |
Pancreatic Elastase/*antagonists & inhibitors | 2 | 50.0 |
Cysteine/genetics | 3 | 2.0 |
*Gene Expression Regulation | 14 | 0.0 |
Protein Precursors/*genetics | 2 | 1.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Rhamnose/*metabolism | 2 | 100.0 |
Fibroblasts/enzymology | 3 | 1.0 |
RNA, Viral/analysis | 2 | 0.0 |
Spain/epidemiology | 4 | 2.0 |
Chromatography, Liquid/*methods | 2 | 12.0 |
Mutation/*genetics | 2 | 0.0 |
Complement Pathway, Alternative/genetics | 2 | 40.0 |
In Situ Hybridization | 5 | 0.0 |
Cyclization | 2 | 22.0 |
Lumbosacral Region | 3 | 10.0 |
Pain Measurement | 4 | 5.0 |
Gestational Age | 6 | 0.0 |
Random Allocation | 4 | 0.0 |
Factor VIII/immunology/*metabolism | 3 | 50.0 |
Cervical Vertebrae/*anatomy & histology/radiography | 2 | 100.0 |
Mast Cells/*enzymology | 2 | 7.0 |
HIV-1/enzymology | 2 | 50.0 |
Complement 1q/analysis | 3 | 17.0 |
Complement 2/analysis | 25 | 86.0 |
Complement 3/analysis | 35 | 10.0 |
Heart Rate/physiology | 2 | 2.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 5 | 1.0 |
Neutrophils/drug effects/*immunology | 2 | 6.0 |
Superoxides/metabolism | 5 | 1.0 |
Immunosuppressive Agents/adverse effects | 2 | 9.0 |
Gene Expression Regulation, Enzymologic | 5 | 0.0 |
Liver/enzymology | 7 | 1.0 |
Prothrombin/*genetics | 2 | 3.0 |
Complement 4/analysis | 30 | 14.0 |
Complement 9/analysis | 4 | 15.0 |
Antigen-Antibody Complex/*immunology | 11 | 13.0 |
Erythrocytes/*immunology | 7 | 3.0 |
Rheumatic Diseases/immunology | 3 | 33.0 |
Complement Factor B/biosynthesis/genetics | 3 | 75.0 |
Adenosine Triphosphate/metabolism | 4 | 0.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Polymers | 3 | 2.0 |
Hemorrhagic Disorders/*immunology | 2 | 100.0 |
Thrombin/pharmacology | 3 | 1.0 |
Movement | 4 | 7.0 |
Apolipoproteins C/*blood | 2 | 6.0 |
Apolipoproteins E/*blood | 2 | 3.0 |
Cholesterol/*blood | 4 | 1.0 |
*Blood Transfusion | 3 | 2.0 |
Liver Transplantation/*physiology | 3 | 15.0 |
Neoplasm Recurrence, Local/mortality | 2 | 40.0 |
Protein Kinases/metabolism | 4 | 0.0 |
Injections, Intra-Articular | 4 | 16.0 |
Tibial Fractures/classification/radiography/*surgery | 2 | 100.0 |
Chromatography, Gel/*methods | 2 | 25.0 |
*Intestinal Absorption | 2 | 5.0 |
*Chromosome Mapping | 13 | 0.0 |
Interferon Type II/pharmacology | 8 | 1.0 |
Chromosomes, Human, Pair 6 | 6 | 3.0 |
Tumor Necrosis Factor-alpha/*genetics | 5 | 1.0 |
Antineoplastic Agents/*pharmacology | 4 | 0.0 |
Blood Transfusion | 3 | 1.0 |
Infant Mortality | 2 | 13.0 |
*Pregnancy Outcome | 2 | 3.0 |
Epitopes/genetics/immunology | 2 | 5.0 |
Prevalence | 7 | 0.0 |
Drug Resistance, Microbial | 6 | 3.0 |
Genes, env | 4 | 6.0 |
Fibroblast Growth Factor 2/pharmacology | 3 | 1.0 |
Recombinant Fusion Proteins/biosynthesis | 4 | 0.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Hemophilia A/blood/*immunology | 2 | 40.0 |
DNA, Viral | 8 | 5.0 |
HIV Envelope Protein gp120/genetics | 3 | 8.0 |
HIV-1/*classification/*genetics/isolation & purification | 2 | 33.0 |
Recombination, Genetic | 11 | 1.0 |
Spinal Fusion/instrumentation | 3 | 100.0 |
Spinal Nerve Roots/*anatomy & histology | 2 | 100.0 |
DNA/*analysis | 4 | 1.0 |
Deoxyribonucleases, Type II Site-Specific | 4 | 1.0 |
*Haplotypes | 10 | 4.0 |
Linkage Disequilibrium | 3 | 0.0 |
Transferrin/*genetics | 14 | 28.0 |
Colonic Neoplasms/*pathology | 3 | 3.0 |
Complement 1/physiology | 2 | 66.0 |
Complement 2/*physiology | 4 | 80.0 |
Complement 4/*physiology | 4 | 80.0 |
*Complement Pathway, Alternative | 17 | 15.0 |
Egtazic Acid/pharmacology | 9 | 8.0 |
*Hemolysis | 12 | 14.0 |
Translocation, Genetic | 2 | 0.0 |
Complement/*biosynthesis | 16 | 44.0 |
Complement 3/biosynthesis | 7 | 25.0 |
Complement 4/biosynthesis | 6 | 37.0 |
Bronchial Provocation Tests | 4 | 5.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Leukemia, Promyelocytic, Acute | 3 | 5.0 |
Mitochondria/*metabolism | 2 | 1.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Sphingolipids/pharmacology | 2 | 66.0 |
Antigen-Antibody Complex/*physiology | 2 | 20.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Subcellular Fractions/immunology | 2 | 15.0 |
Cytotoxicity, Immunologic | 5 | 0.0 |
Liposomes | 3 | 1.0 |
Phospholipids/*metabolism | 8 | 6.0 |
Chromatography, Liquid | 3 | 2.0 |
Complement 4/*metabolism | 12 | 27.0 |
*Antigen-Antibody Reactions | 4 | 10.0 |
Hemophilia A/drug therapy/*immunology | 3 | 42.0 |
*Immunodominant Epitopes | 2 | 22.0 |
*External Fixators | 3 | 100.0 |
Neoplasm Invasiveness | 7 | 0.0 |
Preoperative Care | 7 | 4.0 |
Cats | 8 | 2.0 |
Spinal Cord/*physiology | 5 | 45.0 |
*Gene Expression | 4 | 0.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Phospholipase C/metabolism | 3 | 1.0 |
*Phenotype | 3 | 1.0 |
Carcinoma, Hepatocellular | 5 | 1.0 |
Signal Transduction/drug effects/genetics | 2 | 5.0 |
Disease-Free Survival | 7 | 0.0 |
Prostate-Specific Antigen/blood | 2 | 2.0 |
Radiotherapy Dosage | 14 | 9.0 |
Peptide Fragments/genetics | 2 | 2.0 |
Biological Markers | 5 | 0.0 |
Growth Substances/pharmacology | 2 | 1.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Ploidies | 3 | 1.0 |
Glycoproteins/chemistry | 3 | 11.0 |
Cyclosporine/*blood/pharmacokinetics/therapeutic use | 4 | 100.0 |
Complement Pathway, Classical/*physiology | 4 | 36.0 |
Complement/*metabolism | 35 | 20.0 |
Serine Endopeptidases/*blood | 2 | 22.0 |
HIV Infections/metabolism | 2 | 14.0 |
Heart Rate/*drug effects | 2 | 6.0 |
Sperm Motility/*drug effects | 2 | 11.0 |
Taiwan | 3 | 1.0 |
DNA Fragmentation | 2 | 0.0 |
*Blood Urea Nitrogen | 3 | 75.0 |
*Genes, ras | 3 | 1.0 |
*Point Mutation | 6 | 0.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 3 | 1.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Antigens, CD4/analysis | 3 | 0.0 |
Antigens, CD8/analysis | 2 | 0.0 |
HLA-DR3 Antigen/*analysis | 2 | 28.0 |
Histocompatibility Testing | 17 | 2.0 |
Enzyme Precursors/*metabolism | 6 | 5.0 |
Brazil | 3 | 1.0 |
Complement Factor B/genetics | 36 | 51.0 |
*Gene Frequency | 10 | 1.0 |
Complement 4/metabolism | 31 | 31.0 |
Complement Factor H/metabolism | 2 | 15.0 |
Interferons/pharmacology | 2 | 2.0 |
Ultraviolet Rays | 3 | 0.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
Methionine/metabolism | 7 | 5.0 |
Myocardium/*metabolism | 2 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
Genetics, Population | 7 | 1.0 |
*Genotype | 3 | 1.0 |
Korea | 4 | 1.0 |
Fracture Fixation/*methods | 2 | 22.0 |
Disease Outbreaks | 4 | 6.0 |
Evoked Potentials | 3 | 5.0 |
Atlanto-Axial Joint/*radiography | 2 | 66.0 |
Comorbidity | 2 | 0.0 |
Taiwan/epidemiology | 3 | 2.0 |
Protein Transport/physiology | 2 | 1.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Agrin/metabolism/pharmacology | 2 | 50.0 |
Muscles/*metabolism | 7 | 9.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Quinones/pharmacology | 2 | 1.0 |
Chromatography | 2 | 1.0 |
Restriction Mapping | 25 | 1.0 |
Age of Onset | 2 | 0.0 |
Founder Effect | 2 | 1.0 |
Stochastic Processes | 2 | 5.0 |
Oxygen Consumption | 6 | 2.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
Cerebral Angiography | 2 | 7.0 |
HIV Envelope Protein gp120/*chemistry | 3 | 18.0 |
Peptide Mapping | 5 | 1.0 |
Serine Endopeptidases | 5 | 20.0 |
Alkylation | 3 | 4.0 |
Clone Cells | 4 | 0.0 |
Receptors, Estrogen/*metabolism | 2 | 0.0 |
*Fossils | 2 | 66.0 |
Arachidonic Acid/pharmacology | 2 | 4.0 |
Protein Kinase C/*antagonists & inhibitors | 2 | 6.0 |
Trypsin/pharmacology | 4 | 2.0 |
Complement Factor B/*analysis/immunology | 2 | 100.0 |
Epitopes/analysis | 6 | 2.0 |
Chemistry, Physical | 7 | 5.0 |
Hemoglobin A/chemistry/genetics | 2 | 66.0 |
Oxygen/chemistry | 3 | 21.0 |
*Cations | 2 | 66.0 |
Chimeric Proteins | 2 | 2.0 |
Gene Expression/physiology | 2 | 0.0 |
Hepatocyte Growth Factor/*pharmacology | 2 | 1.0 |
Length of Stay | 2 | 2.0 |
Thrombin/*metabolism | 2 | 2.0 |
Arginine | 2 | 2.0 |
Cysteine | 3 | 2.0 |
Regeneration | 2 | 3.0 |
Chromatography, Gas | 3 | 3.0 |
Chemotaxis, Leukocyte | 5 | 2.0 |
Neutrophils/*immunology | 4 | 2.0 |
Placenta | 2 | 4.0 |
*Twins | 4 | 14.0 |
Erythrocytes/*chemistry | 2 | 5.0 |
Isoelectric Focusing | 30 | 5.0 |
Gene Expression/drug effects | 3 | 0.0 |
Gene Transfer Techniques | 3 | 0.0 |
*Brain Chemistry | 3 | 1.0 |
Complement 4/*deficiency/genetics | 3 | 18.0 |
Lupus Erythematosus, Systemic/*immunology/metabolism | 2 | 18.0 |
Colorectal Neoplasms/*pathology | 2 | 3.0 |
Hydroxylation | 4 | 1.0 |
Methylation | 2 | 0.0 |
Superantigens/*immunology | 2 | 2.0 |
Carcinoembryonic Antigen/*blood | 2 | 8.0 |
Tumor Markers, Biological/*blood | 3 | 0.0 |
*Spinal Fusion | 2 | 66.0 |
Autoantibodies/blood | 2 | 1.0 |
*Blood Donors | 2 | 1.0 |
HLA-A Antigens/*genetics | 2 | 1.0 |
HLA-B Antigens/*genetics | 4 | 1.0 |
Complement/*biosynthesis/genetics | 7 | 87.0 |
Epithelial Cells | 3 | 0.0 |
Glomerulonephritis/etiology/immunology | 2 | 50.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
*Exercise | 3 | 2.0 |
*Tomography, Emission-Computed, Single-Photon | 2 | 6.0 |
Intercellular Adhesion Molecule-1/*blood | 2 | 3.0 |
Interleukin-6/*blood | 2 | 0.0 |
*Phylogeny | 6 | 3.0 |
Selection (Genetics) | 3 | 2.0 |
Vero Cells | 2 | 0.0 |
Microsatellite Repeats/genetics | 3 | 0.0 |
Arthritis, Rheumatoid/*genetics | 3 | 4.0 |
Leukocyte Count | 4 | 0.0 |
Liver Function Tests | 2 | 1.0 |
*Prostheses and Implants | 2 | 9.0 |
*Bacterial Typing Techniques | 3 | 21.0 |
Salmonella Phages | 2 | 66.0 |
Properdin/analysis | 5 | 27.0 |
Syndrome | 11 | 0.0 |
*Genes, Retinoblastoma | 2 | 1.0 |
Immunoglobulins/metabolism | 3 | 2.0 |
Membrane Glycoproteins/genetics/*metabolism | 2 | 1.0 |
Antibody Affinity | 4 | 2.0 |
*Disulfides | 2 | 33.0 |
Follicle Stimulating Hormone/blood | 2 | 0.0 |
Protein Kinase C/*chemistry/metabolism | 2 | 66.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
India | 4 | 1.0 |
Likelihood Functions | 3 | 1.0 |
*Skin Absorption | 2 | 40.0 |
Anticholesteremic Agents/*therapeutic use | 2 | 3.0 |
Salmonella Infections/*epidemiology/microbiology | 2 | 100.0 |
Protein-Serine-Threonine Kinases/metabolism | 3 | 0.0 |
Pattern Recognition, Visual/*physiology | 2 | 9.0 |
Polyethylene Glycols | 2 | 2.0 |
Fluorouracil/therapeutic use | 4 | 8.0 |
Glycolysis | 2 | 3.0 |
Leukemia, Erythroblastic, Acute | 3 | 3.0 |
Complement 4/*genetics | 28 | 20.0 |
England | 4 | 3.0 |
Complement 1s/biosynthesis | 2 | 66.0 |
Complement 2/biosynthesis | 15 | 93.0 |
*Blood Coagulation | 3 | 1.0 |
Fibrinolysis | 4 | 2.0 |
Kallikreins/*metabolism | 2 | 12.0 |
Aging/*physiology | 3 | 1.0 |
Blood Pressure | 5 | 0.0 |
Hemodynamic Processes | 3 | 1.0 |
Genes, MHC Class I | 5 | 4.0 |
Genes, MHC Class II | 15 | 6.0 |
Colonic Neoplasms/epidemiology/*pathology | 2 | 66.0 |
Cyclosporine/administration & dosage/*blood/therapeutic use | 2 | 100.0 |
Immunosuppressive Agents/*blood | 2 | 22.0 |
Transplantation, Homologous | 6 | 0.0 |
Phospholipases A/genetics/*metabolism | 2 | 28.0 |
Cell Line, Tumor | 10 | 0.0 |
Models, Statistical | 4 | 2.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
China/epidemiology | 2 | 1.0 |
Biological Transport/physiology | 2 | 1.0 |
Laterality/physiology | 2 | 3.0 |
Postoperative Complications/diagnosis | 2 | 20.0 |
Cervical Vertebrae/*physiology | 2 | 100.0 |
Antigens, CD4/immunology | 2 | 1.0 |
HIV Antibodies/immunology | 4 | 6.0 |
History, Ancient | 2 | 11.0 |
Cell Compartmentation/drug effects | 2 | 10.0 |
Oligodeoxyribonucleotides/chemistry | 4 | 1.0 |
Autoantibodies/*blood | 2 | 0.0 |
Complement/*deficiency | 26 | 56.0 |
Complement Hemolytic Activity Assay | 7 | 14.0 |
Lupus Erythematosus, Systemic/*immunology | 13 | 8.0 |
Electrophoresis/methods | 2 | 2.0 |
Blood Physiology | 2 | 2.0 |
Complement Inactivators/pharmacology | 5 | 41.0 |
*Sex Characteristics | 2 | 1.0 |
*Neck | 2 | 25.0 |
Range of Motion, Articular | 3 | 13.0 |
Spinal Cord/*anatomy & histology | 3 | 100.0 |
Complement/*deficiency/genetics | 3 | 75.0 |
Electron Spin Resonance Spectroscopy/methods | 3 | 13.0 |
Hydrogen | 2 | 9.0 |
Complement Pathway, Alternative/*genetics | 2 | 50.0 |
Dysgammaglobulinemia/genetics | 2 | 66.0 |
*Homozygote | 2 | 1.0 |
Aldehydes/*pharmacology | 2 | 11.0 |
Escherichia coli/metabolism | 3 | 1.0 |
*Complement 4b | 2 | 6.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
Chromosome Banding | 3 | 0.0 |
*Genes, myc | 2 | 0.0 |
Vasculitis/*complications | 3 | 37.0 |
Protein Kinase C/*metabolism | 3 | 1.0 |
Chromatography, High Pressure Liquid/*methods/statistics & numerical data | 2 | 40.0 |
Aging/physiology | 3 | 1.0 |
C-Reactive Protein/metabolism | 2 | 0.0 |
Electrophoresis | 5 | 1.0 |
alpha-Fetoproteins/analysis | 2 | 0.0 |
Peptide Fragments/genetics/immunology | 3 | 8.0 |
Magnesium/pharmacology | 6 | 5.0 |
Cyclic AMP/blood | 2 | 5.0 |
Platelet Aggregation Inhibitors/pharmacology | 2 | 3.0 |
Galactosylceramides/metabolism | 2 | 14.0 |
Cosmids | 7 | 1.0 |
DNA/chemistry | 5 | 1.0 |
L Cells (Cell Line) | 3 | 1.0 |
Nuclear Family | 3 | 1.0 |
Phenylalanine | 3 | 11.0 |
Recombinant Proteins/analysis/biosynthesis | 2 | 9.0 |
Skin/metabolism | 3 | 1.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 2 | 1.0 |
Regulatory Sequences, Nucleic Acid | 5 | 0.0 |
Aging/*metabolism | 2 | 0.0 |
Blood Proteins/*analysis | 4 | 2.0 |
Lactoferrin/*chemistry/metabolism | 2 | 100.0 |
Quality Control | 6 | 3.0 |
Graft Rejection/prevention & control | 3 | 7.0 |
Immunosuppressive Agents/*therapeutic use | 3 | 2.0 |
Heart Transplantation/*immunology | 4 | 6.0 |
Kidney Transplantation/*immunology/physiology | 4 | 33.0 |
Mycophenolic Acid/*analogs & derivatives/therapeutic use | 3 | 25.0 |
Kidney Transplantation/immunology/physiology | 2 | 33.0 |
Cyclosporine/*blood/pharmacokinetics/*therapeutic use | 2 | 100.0 |
Immunosuppressive Agents/administration & dosage/blood/therapeutic use | 2 | 100.0 |
Biological Availability | 5 | 1.0 |
Intestinal Absorption | 6 | 4.0 |
Cyclosporine/*blood/pharmacokinetics | 4 | 100.0 |
Immunosuppressive Agents/blood/pharmacokinetics | 2 | 66.0 |
Liver Transplantation/*immunology | 3 | 9.0 |
Tacrolimus/*therapeutic use | 3 | 23.0 |
Graft Rejection/immunology/prevention & control | 2 | 33.0 |
Clinical Trials | 9 | 0.0 |
Cyclosporine/*therapeutic use | 2 | 6.0 |
Prostate-Specific Antigen | 3 | 2.0 |
Exocytosis | 2 | 2.0 |
Acetylglucosamine/metabolism | 2 | 18.0 |
Complement 4/*deficiency | 4 | 44.0 |
Antibodies, Bacterial/*immunology | 3 | 12.0 |
*Antigens, Bacterial | 4 | 7.0 |
*Bacterial Outer Membrane Proteins | 3 | 18.0 |
Alcoholism/ethnology/*genetics | 2 | 22.0 |
Cytochrome P-450 CYP2E1 | 5 | 4.0 |
Gene Frequency/genetics | 3 | 0.0 |
Heterozygote Detection | 2 | 0.0 |
Oxidoreductases, N-Demethylating/*genetics | 4 | 9.0 |
Complement/genetics | 10 | 37.0 |
Registries | 2 | 0.0 |
Oligodeoxyribonucleotides | 10 | 1.0 |
Spectrum Analysis, Mass/methods | 2 | 5.0 |
Platelet Aggregation/*drug effects | 3 | 2.0 |
Neutropenia/*etiology | 2 | 22.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Complement 4/*deficiency/physiology | 2 | 100.0 |
HLA Antigens/analysis/*genetics | 2 | 5.0 |
HLA-D Antigens/genetics | 3 | 7.0 |
*Brain Mapping | 2 | 4.0 |
Energy Metabolism | 2 | 1.0 |
Glucose/administration & dosage/*metabolism | 2 | 40.0 |
HIV Protease Inhibitors/chemistry/*pharmacology | 2 | 50.0 |
HIV-1/*drug effects/enzymology/genetics | 2 | 22.0 |
*Phagocytosis | 4 | 3.0 |
Prednisolone/therapeutic use | 2 | 2.0 |
Remission Induction | 2 | 0.0 |
Ionophores/pharmacology | 2 | 1.0 |
Cytokines/*biosynthesis | 2 | 0.0 |
Immunity, Cellular | 3 | 0.0 |
*Lymphocyte Activation | 3 | 0.0 |
*Genes, Structural | 14 | 1.0 |
Calcium-Binding Proteins/chemistry/*genetics | 2 | 20.0 |
*rab GTP-Binding Proteins | 3 | 5.0 |
Contrast Media | 3 | 5.0 |
Gadolinium/diagnostic use | 2 | 12.0 |
Necrosis | 2 | 0.0 |
Hypercholesterolemia/blood/*drug therapy | 2 | 8.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Skin/pathology | 7 | 2.0 |
Complement 2/*analysis/genetics | 2 | 100.0 |
Complement 4/*analysis/genetics | 2 | 50.0 |
HLA Antigens/analysis | 19 | 7.0 |
Glucuronic Acid | 3 | 15.0 |
Angioneurotic Edema/genetics/*immunology | 2 | 100.0 |
*Complement Activation/drug effects | 4 | 26.0 |
Danazol/pharmacology | 2 | 66.0 |
*Exertion | 3 | 1.0 |
Complement Pathway, Alternative/*drug effects | 4 | 18.0 |
Complement Pathway, Classical/*drug effects | 7 | 41.0 |
Calcitonin Gene-Related Peptide/analysis | 2 | 2.0 |
Ultracentrifugation | 3 | 1.0 |
Methods | 5 | 2.0 |
Graft Rejection | 4 | 2.0 |
Graft Survival | 4 | 1.0 |
Kidney/metabolism | 2 | 0.0 |
Combined Modality Therapy | 25 | 2.0 |
Prostatectomy | 6 | 7.0 |
Macaca fascicularis | 4 | 1.0 |
Isoantibodies/metabolism | 2 | 50.0 |
Chemical Fractionation | 2 | 2.0 |
Glycoproteins/chemistry/metabolism | 2 | 18.0 |
Intervertebral Disk/*surgery | 2 | 100.0 |
Remission, Spontaneous | 3 | 4.0 |
Diglycerides/metabolism | 2 | 4.0 |
Phorbol Esters/metabolism | 2 | 18.0 |
Factor V Deficiency/*genetics | 2 | 50.0 |
Immunoglobulin G/pharmacology | 3 | 5.0 |
HIV Envelope Protein gp41/immunology | 2 | 9.0 |
Bacterial Proteins/*metabolism | 2 | 4.0 |
Immunoglobulin G/*metabolism | 2 | 3.0 |
Peptide Fragments/analysis | 6 | 2.0 |
Adenocarcinoma/*surgery | 3 | 50.0 |
Neoplasm Recurrence, Local/epidemiology | 3 | 15.0 |
Adenocarcinoma/mortality/*radiotherapy/surgery | 2 | 66.0 |
Colonic Neoplasms/mortality/*radiotherapy/surgery | 2 | 100.0 |
Radiotherapy, High-Energy | 2 | 16.0 |
Indicators and Reagents | 5 | 1.0 |
DNA, Complementary/isolation & purification | 2 | 1.0 |
DNA Replication/drug effects | 2 | 1.0 |
Femoral Fractures/radiography/*surgery | 2 | 100.0 |
Fracture Fixation, Intramedullary/*methods | 2 | 100.0 |
Complement Factor B/biosynthesis | 11 | 64.0 |
Fibroblasts/metabolism | 6 | 0.0 |
Sulfur Radioisotopes | 3 | 4.0 |
Biopsy, Needle | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/analysis | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
*Signal Processing, Computer-Assisted | 2 | 6.0 |
Brain Mapping | 2 | 1.0 |
Sensory Thresholds/physiology | 2 | 12.0 |
Flushing/genetics | 2 | 28.0 |
Antigens, CD55 | 4 | 2.0 |
Liposomes/analysis | 2 | 100.0 |
Organ Culture Techniques | 2 | 0.0 |
Attention | 4 | 21.0 |
*Discrimination Learning | 4 | 33.0 |
Mental Recall | 2 | 15.0 |
*Pattern Recognition, Visual | 3 | 25.0 |
Psychomotor Performance | 2 | 6.0 |
Token Economy | 2 | 100.0 |
Complement 1 Inactivators/*deficiency/metabolism | 2 | 66.0 |
Danazol/therapeutic use | 4 | 40.0 |
Enzyme Tests | 2 | 2.0 |
HIV Envelope Protein gp120/genetics/*immunology | 2 | 10.0 |
New York | 4 | 19.0 |
Thailand | 2 | 1.0 |
Uganda | 2 | 7.0 |
HIV Protease Inhibitors/*pharmacology | 2 | 7.0 |
Immunochemistry | 2 | 0.0 |
Oligopeptides/chemistry | 2 | 8.0 |
Biological Markers/blood | 2 | 0.0 |
Urea/*metabolism | 3 | 14.0 |
Genomic Library | 3 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
DNA Probes | 8 | 0.0 |
*Transfection | 3 | 1.0 |
Cobra Venoms/pharmacology | 4 | 28.0 |
Complement/deficiency | 5 | 50.0 |
Coronary Angiography | 2 | 0.0 |
Acylation | 2 | 2.0 |
Esters | 2 | 6.0 |
Ribonucleases/metabolism | 3 | 2.0 |
Templates, Genetic | 3 | 1.0 |
Endotoxins/pharmacology | 2 | 2.0 |
African Continental Ancestry Group | 3 | 1.0 |
RNA, Messenger/isolation & purification/metabolism | 2 | 10.0 |
Complement 2/*biosynthesis/genetics | 2 | 100.0 |
Complement Factor B/*biosynthesis/genetics | 3 | 60.0 |
Monocytes | 2 | 2.0 |
Sulfonamides/pharmacology | 2 | 1.0 |
*Data Interpretation, Statistical | 2 | 15.0 |
Electrodes | 2 | 4.0 |
Mathematics | 5 | 2.0 |
Colonoscopy | 3 | 6.0 |
Hemolytic Plaque Technique | 10 | 16.0 |
*Heterozygote | 3 | 0.0 |
Thermoplasma/enzymology | 2 | 100.0 |
Prostatic Neoplasms/*radiotherapy/surgery | 2 | 100.0 |
Amino Acids/*metabolism | 2 | 5.0 |
*Blood | 2 | 4.0 |
Complement 2/genetics/metabolism | 2 | 100.0 |
*Terminator Regions (Genetics) | 2 | 14.0 |
Chorionic Gonadotropin, beta Subunit, Human | 2 | 4.0 |
Bone Transplantation | 2 | 25.0 |
Vascular Cell Adhesion Molecule-1 | 3 | 3.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Gene Products, env/chemistry/*genetics | 2 | 66.0 |
Bone Plates | 4 | 40.0 |
Fracture Fixation, Internal/*instrumentation | 2 | 100.0 |
*Cervical Vertebrae/radiography | 2 | 9.0 |
Reaction Time | 4 | 3.0 |
Antibodies, Monoclonal/analysis | 2 | 2.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
Monocytes/immunology | 8 | 2.0 |
Skin/immunology | 6 | 6.0 |
Cell Membrane Permeability | 2 | 1.0 |
Adrenal Hyperplasia, Congenital/genetics/immunology | 2 | 100.0 |
Complement 2/deficiency | 22 | 95.0 |
Complement 3/genetics | 9 | 25.0 |
Diabetes Mellitus, Type 1/genetics/immunology | 2 | 16.0 |
Receptors, Complement/genetics | 4 | 26.0 |
Half-Life | 8 | 1.0 |
DNA-Binding Proteins/*analysis | 2 | 3.0 |
Ribonucleases/pharmacology | 2 | 28.0 |
HIV Protease/*metabolism | 2 | 40.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Rabbits/immunology | 6 | 6.0 |
Heart Arrest, Induced | 2 | 20.0 |
Genes, Recessive | 5 | 1.0 |
Serum Albumin/*metabolism | 2 | 4.0 |
Life Tables | 3 | 1.0 |
Lymph Node Excision | 3 | 4.0 |
Lupus Erythematosus, Systemic/ethnology/*genetics | 2 | 20.0 |
Major Histocompatibility Complex/genetics | 3 | 5.0 |
Immunosuppressive Agents/*blood/pharmacokinetics | 3 | 100.0 |
Complement/immunology | 6 | 6.0 |
Microspheres | 2 | 1.0 |
Cluster Analysis | 3 | 1.0 |
Ion Channel Gating | 2 | 2.0 |
Complement Factor B/*chemistry | 2 | 100.0 |
*Protein Structure, Secondary | 4 | 2.0 |
Immunoglobulins, Fab | 2 | 3.0 |
Peptides/chemical synthesis/pharmacology | 2 | 25.0 |
Sarcoma 180/drug therapy | 2 | 50.0 |
Radiotherapy/adverse effects | 3 | 8.0 |
Angioneurotic Edema/immunology | 4 | 66.0 |
Complement 1r/*metabolism | 2 | 28.0 |
Complement 2/physiology | 3 | 100.0 |
Edetic Acid/pharmacology | 13 | 7.0 |
Cyclosporine/*blood/therapeutic use | 2 | 66.0 |
Immunosuppressive Agents/*blood/therapeutic use | 2 | 66.0 |
*Premedication | 2 | 16.0 |
Complement 4a/*genetics | 3 | 8.0 |
Proteins/*genetics | 2 | 0.0 |
*Transcription Factors | 2 | 0.0 |
*Phonetics | 2 | 14.0 |
Speech/*physiology | 2 | 16.0 |
Speech Production Measurement | 2 | 16.0 |
Genes, Viral | 3 | 1.0 |
Muscles/cytology/*metabolism | 3 | 21.0 |
Poly A/isolation & purification/metabolism | 2 | 28.0 |
RNA/isolation & purification/metabolism | 2 | 14.0 |
RNA, Messenger/biosynthesis/metabolism | 2 | 4.0 |
Desmin/*genetics | 2 | 25.0 |
Complement 3/*biosynthesis/genetics | 3 | 17.0 |
Complement Factor H/*biosynthesis/genetics | 2 | 100.0 |
Interleukin-1/*pharmacology | 3 | 0.0 |
Acoustic Stimulation | 2 | 2.0 |
Thymidylate Synthase/*antagonists & inhibitors | 2 | 10.0 |
*Tomography, X-Ray Computed | 2 | 2.0 |
Arthritis, Rheumatoid/*immunology | 5 | 2.0 |
Complement 4b/*genetics | 3 | 8.0 |
*Disease Models, Animal | 2 | 0.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Recombinant Proteins/chemistry/genetics | 2 | 3.0 |
Complement/analysis/*deficiency | 4 | 57.0 |
Complement Fixation Tests | 15 | 16.0 |
Complement Pathway, Alternative/drug effects | 7 | 33.0 |
Complement Pathway, Classical/drug effects | 7 | 30.0 |
Disulfides/*chemistry | 2 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Myosins/*metabolism | 2 | 10.0 |
Peptide Fragments/isolation & purification | 5 | 8.0 |
Cell Adhesion Molecules/*genetics | 2 | 2.0 |
*Evolution | 3 | 1.0 |
Complement 2/*chemistry | 2 | 100.0 |
Evolution | 4 | 1.0 |
Agglutination | 4 | 23.0 |
Antigens, Bacterial/*analysis | 2 | 11.0 |
*Bacteriophage Typing | 2 | 66.0 |
Carboxylic Acids/metabolism | 2 | 28.0 |
Methylglucosides/metabolism | 2 | 28.0 |
Antigen-Antibody Complex/*metabolism | 4 | 5.0 |
Liver/immunology | 3 | 6.0 |
Plasma/immunology | 2 | 22.0 |
X Chromosome | 2 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Disulfides | 2 | 2.0 |
Moths | 2 | 4.0 |
Scattering, Radiation | 3 | 2.0 |
Cloning, Molecular/methods | 3 | 1.0 |
N-Acetylneuraminic Acid | 3 | 7.0 |
*Virus Replication | 2 | 0.0 |
*Enzyme-Linked Immunosorbent Assay | 2 | 2.0 |
False Negative Reactions | 2 | 1.0 |
False Positive Reactions | 2 | 0.0 |
Hepacivirus/*immunology | 2 | 6.0 |
Hepatitis Antibodies/*blood | 2 | 33.0 |
Hepatitis C Antibodies | 2 | 16.0 |
HIV-1/*enzymology | 2 | 11.0 |
*Environment | 3 | 6.0 |
Pulmonary Gas Exchange | 2 | 8.0 |
Muscles/*enzymology | 2 | 2.0 |
RNA, Messenger | 2 | 0.0 |
Autoanalysis | 3 | 11.0 |
Macrophage-1 Antigen/*physiology | 2 | 10.0 |
Opsonins | 3 | 7.0 |
Phagocytosis | 7 | 1.0 |
Serine Endopeptidases/metabolism | 3 | 2.0 |
Trypsin/metabolism | 4 | 2.0 |
Complement 9/genetics | 2 | 33.0 |
Macrophages/*metabolism | 3 | 1.0 |
Monocytes/*metabolism | 7 | 1.0 |
Complement 3d/*metabolism | 2 | 18.0 |
Dithiothreitol/pharmacology | 2 | 2.0 |
Rosette Formation | 5 | 1.0 |
Complement 2/analysis/*deficiency | 6 | 100.0 |
Exercise Test | 3 | 1.0 |
Drug Storage | 2 | 33.0 |
Complement 3/*metabolism | 5 | 3.0 |
Chemistry | 19 | 9.0 |
Phagocytosis/drug effects | 3 | 3.0 |
Immunoglobulin G/analysis | 12 | 3.0 |
Histocytochemistry | 3 | 0.0 |
Dyes/pharmacology | 2 | 2.0 |
Phosphoric Monoester Hydrolases/*metabolism | 3 | 3.0 |
Tumor Suppressor Proteins/*metabolism | 3 | 3.0 |
Torpedo | 2 | 5.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Intestinal Mucosa/metabolism | 2 | 1.0 |
Staining and Labeling | 4 | 0.0 |
Sweden | 4 | 1.0 |
Antibodies, Protozoan/*blood | 2 | 16.0 |
Plasmodium falciparum/*immunology | 2 | 4.0 |
DNA/genetics | 17 | 0.0 |
Graves' Disease/*genetics/immunology | 2 | 18.0 |
*Blood Bactericidal Activity | 4 | 8.0 |
Carrier Proteins/*analysis | 3 | 3.0 |
Mice, Inbred ICR | 2 | 0.0 |
Amino Acids/analysis | 10 | 3.0 |
Hemagglutination | 2 | 5.0 |
Hemagglutination Inhibition Tests | 3 | 6.0 |
Mannose/metabolism | 2 | 6.0 |
Adenocarcinoma/drug therapy | 2 | 15.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Complement 1/deficiency | 5 | 100.0 |
Complement 4/deficiency | 13 | 54.0 |
Complement Factor D/deficiency | 2 | 100.0 |
Chimeric Proteins/chemistry/genetics/metabolism | 2 | 4.0 |
Twins, Dizygotic | 3 | 8.0 |
Twins, Monozygotic | 3 | 3.0 |
Erythrocyte Membrane/enzymology | 2 | 12.0 |
Liver Neoplasms, Experimental | 2 | 4.0 |
Complement 2/*analysis | 5 | 83.0 |
Hybridomas/immunology | 2 | 1.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Leukocytes, Mononuclear/*metabolism | 2 | 1.0 |
Cyanogen Bromide | 3 | 5.0 |
*Serine Endopeptidases | 3 | 8.0 |
Antigen-Antibody Reactions | 6 | 1.0 |
Enzyme Stability | 2 | 1.0 |
HLA-A Antigens/genetics | 3 | 1.0 |
HLA-B Antigens/genetics | 6 | 2.0 |
DNA/*genetics/isolation & purification | 2 | 3.0 |
Interferon-gamma, Recombinant/*pharmacology | 2 | 1.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Chromatography, High Pressure Liquid/methods | 3 | 2.0 |
Chlorides/*metabolism | 2 | 2.0 |
Hemolysis/drug effects | 7 | 11.0 |
Asthma/immunology | 2 | 5.0 |
Immunoglobulin E/analysis | 2 | 3.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
Antibodies, Antinuclear/analysis | 9 | 12.0 |
Antigen-Antibody Complex/analysis | 8 | 7.0 |
Lupus Nephritis/immunology | 2 | 40.0 |
Endothelium, Vascular/*enzymology | 2 | 4.0 |
Colectomy | 2 | 7.0 |
Adenosine-5'-(N-ethylcarboxamide) | 2 | 50.0 |
Adenylate Cyclase/metabolism | 3 | 2.0 |
Radioligand Assay | 2 | 0.0 |
Phenylethanolamine N-Methyltransferase/*analysis | 2 | 28.0 |
*IgA Deficiency | 2 | 11.0 |
DNA Replication | 2 | 0.0 |
Complement 4b/genetics | 3 | 14.0 |
HLA-DQ Antigens/genetics | 5 | 1.0 |
*Chromosome Deletion | 2 | 0.0 |
*Exons | 3 | 0.0 |
*RNA Splicing | 5 | 1.0 |
Endopeptidases | 4 | 11.0 |
Complement 1q/*metabolism | 2 | 10.0 |
Antigens, Fungal/*analysis | 2 | 100.0 |
Candida/*immunology | 2 | 25.0 |
Latex Fixation Tests | 2 | 7.0 |
Lung Diseases/*immunology | 2 | 16.0 |
Lung Diseases, Fungal/*immunology | 2 | 66.0 |
Reagent Kits, Diagnostic | 3 | 2.0 |
Respiratory Tract Infections/*immunology | 2 | 25.0 |
Aneurysm/*etiology/radiography/surgery | 2 | 100.0 |
Carotid Artery Diseases/*complications/radiography/surgery | 2 | 100.0 |
Carotid Artery, Internal/radiography | 2 | 50.0 |
Fibromuscular Dysplasia/*complications/radiography | 2 | 100.0 |
Androstenols/chemistry/*metabolism/urine | 2 | 100.0 |
Glucuronates/chemistry | 2 | 66.0 |
Mesterolone/chemistry/*metabolism/urine | 2 | 100.0 |
Methenolone/chemistry/*metabolism/urine | 2 | 100.0 |
Steroid Hydroxylases/metabolism | 2 | 3.0 |
Sulfates/chemistry | 2 | 16.0 |
Antibodies/physiology | 2 | 20.0 |
Actins/*physiology | 2 | 5.0 |
*HIV Protease Inhibitors | 2 | 100.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Immunoglobulins, kappa-Chain/*genetics | 2 | 9.0 |
Complement 1 Inactivators/deficiency | 3 | 60.0 |
Complement 3/*deficiency | 2 | 15.0 |
Streptococcus pneumoniae/*immunology | 3 | 9.0 |
Deoxyribonucleotides | 2 | 28.0 |
Ceramides/*metabolism | 2 | 8.0 |
HLA Antigens/genetics/*immunology | 3 | 4.0 |
HLA-DR Antigens/genetics/immunology | 2 | 6.0 |
Haploidy | 12 | 10.0 |
Metaphase | 2 | 1.0 |
Complement/*genetics/metabolism | 2 | 100.0 |
Complement Factor H | 13 | 17.0 |
Integrin alphaXbeta2 | 10 | 27.0 |
Gastrectomy | 2 | 3.0 |
Gastric Mucosa/*pathology | 2 | 8.0 |
China | 6 | 1.0 |
*Genetics, Population | 4 | 1.0 |
DNA/isolation & purification | 2 | 1.0 |
*Indoles | 2 | 18.0 |
Antibodies/*immunology | 2 | 1.0 |
Pemphigus/immunology | 2 | 22.0 |
Fatty Acids, Unsaturated/*pharmacology | 2 | 6.0 |
Cyclosporine/*blood | 3 | 50.0 |
Complement 6/metabolism | 3 | 30.0 |
Liver Cirrhosis, Biliary/*immunology | 3 | 8.0 |
Antigens, Viral/*immunology | 3 | 3.0 |
Tumor Necrosis Factor-alpha/genetics | 4 | 1.0 |
Complement Pathway, Classical/immunology | 2 | 22.0 |
Immunodiffusion | 17 | 6.0 |
Cysteine Endopeptidases/*genetics | 2 | 6.0 |
Multienzyme Complexes/*genetics | 2 | 2.0 |
Complement 1 Inactivators/*biosynthesis | 3 | 50.0 |
Monocytes/*immunology | 9 | 2.0 |
Proto-Oncogene Proteins c-myc/*genetics | 2 | 4.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 6 | 10.0 |
*Genetic Markers | 3 | 0.0 |
Complement 1 Inactivators/genetics | 2 | 66.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Indomethacin/pharmacology | 3 | 1.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Spectrophotometry, Atomic | 2 | 4.0 |
Pyridines/*pharmacology | 2 | 3.0 |
Botulinum Toxins/*pharmacology | 2 | 50.0 |
Gene Expression Regulation/drug effects | 6 | 0.0 |
Complement 1 Inactivators/*deficiency | 6 | 85.0 |
Deoxyribonuclease HpaII | 2 | 2.0 |
Histamine/pharmacology | 3 | 5.0 |
DNA, Mitochondrial/*genetics | 2 | 1.0 |
Immune Adherence Reaction | 6 | 13.0 |
Receptors, Complement/analysis | 2 | 3.0 |
Factor VIII/*genetics | 2 | 5.0 |
Hemophilia A/*genetics | 2 | 9.0 |
Diabetes Mellitus, Type 1/*genetics | 4 | 1.0 |
Arthritis, Rheumatoid/genetics/*metabolism | 2 | 50.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Hematopoietic Stem Cells/*pathology | 2 | 2.0 |
Nitrogen | 3 | 33.0 |
Bayes Theorem | 2 | 3.0 |
Angioneurotic Edema/*immunology | 2 | 40.0 |
Complement/isolation & purification | 2 | 50.0 |
Immunologic Deficiency Syndromes/complications | 4 | 57.0 |
*Generalization, Stimulus | 2 | 100.0 |
*Psychomotor Performance | 2 | 15.0 |
Immunologic Deficiency Syndromes/*complications/genetics | 2 | 66.0 |
Factor VIII/*genetics/immunology | 2 | 100.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Insulin/*therapeutic use | 2 | 2.0 |
Genes | 8 | 3.0 |
*Antibody Formation | 3 | 3.0 |
Heparin/pharmacology | 2 | 0.0 |
Complement 1/*metabolism | 5 | 19.0 |
Drug Evaluation | 3 | 1.0 |
Evoked Potentials, Somatosensory/*physiology | 2 | 7.0 |
Tibial Nerve/*physiology | 3 | 50.0 |
Range of Motion, Articular/physiology | 3 | 23.0 |
Anatomy, Cross-Sectional | 2 | 25.0 |
Mandible | 2 | 11.0 |
Odontometry | 2 | 50.0 |
*Genes, MHC Class I | 2 | 0.0 |
*Genes, MHC Class II | 6 | 1.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
Histocompatibility Antigens Class II/analysis | 5 | 2.0 |
Psoriasis/*genetics/immunology | 2 | 15.0 |
*Movement | 3 | 23.0 |
Complement 2/*biosynthesis/genetics/secretion | 2 | 100.0 |
HLA Antigens/immunology | 3 | 1.0 |
Hydralazine/adverse effects | 2 | 100.0 |
Isoniazid/adverse effects | 2 | 66.0 |
Lupus Erythematosus, Systemic/genetics/*immunology | 5 | 15.0 |
Penicillamine/adverse effects | 2 | 33.0 |
*Models, Biological | 2 | 1.0 |
Glomerulonephritis/*immunology | 2 | 5.0 |
Lamins | 2 | 3.0 |
Capsid/*immunology | 2 | 15.0 |
Hybridomas | 2 | 1.0 |
Chromosome Aberrations | 2 | 0.0 |
Czechoslovakia | 2 | 11.0 |
*Neoplasm Recurrence, Local | 3 | 6.0 |
Bacterial Infections/*immunology | 2 | 6.0 |
Interferons/*pharmacology | 4 | 5.0 |
*Cloning, Molecular | 7 | 2.0 |
DNA/genetics/isolation & purification | 6 | 2.0 |
Liver Neoplasms | 5 | 1.0 |
Interferon-gamma, Recombinant/pharmacology | 4 | 2.0 |
Running | 2 | 5.0 |
Bacterial Infections/immunology | 5 | 20.0 |
Complement/*deficiency/genetics/physiology | 2 | 100.0 |
Inflammation/immunology | 3 | 2.0 |
Denmark | 3 | 1.0 |
HLA-C Antigens/genetics | 2 | 2.0 |
Brain/*enzymology | 2 | 1.0 |
Deoxyribonuclease I | 2 | 1.0 |
Hela Cells/enzymology | 2 | 5.0 |
Nucleotide Mapping | 2 | 4.0 |
Lipid Bilayers/chemistry | 2 | 15.0 |
Complement 1/metabolism | 13 | 34.0 |
Fetal Blood/immunology | 2 | 2.0 |
Serum Albumin/pharmacology | 3 | 8.0 |
Urticaria/complications | 2 | 100.0 |
Urticaria/*immunology | 2 | 33.0 |
Complement 3b Inactivators/metabolism | 5 | 20.0 |
Complement Activating Enzymes/*antagonists & inhibitors | 3 | 50.0 |
Glass | 2 | 7.0 |
Phosphorylcholine/pharmacology | 2 | 18.0 |
HLA Antigens/genetics | 29 | 9.0 |
*Bacterial Toxins | 2 | 1.0 |
Receptors, Cell Surface/*blood | 2 | 11.0 |
*Superantigens | 2 | 4.0 |
Complement/biosynthesis | 2 | 28.0 |
Complement 3b Inactivators/biosynthesis | 2 | 100.0 |
Complement Factor B/*biosynthesis | 6 | 50.0 |
Enzyme Precursors/*biosynthesis | 8 | 72.0 |
Skin/*metabolism | 2 | 1.0 |
Interferon Type I/pharmacology | 3 | 6.0 |
Lupus Erythematosus, Systemic/complications/*genetics | 2 | 40.0 |
Lupus Erythematosus, Systemic/genetics | 3 | 25.0 |
Nucleic Acid Hybridization | 9 | 0.0 |
*Radioimmunoassay | 3 | 7.0 |
Complement 4a/genetics | 2 | 10.0 |
Lupus Erythematosus, Systemic/*complications | 2 | 11.0 |
Enzyme Precursors/*genetics | 22 | 19.0 |
*Ethnic Groups | 2 | 1.0 |
Leukocytes/*enzymology | 2 | 3.0 |
Blood Proteins/metabolism | 4 | 1.0 |
Feces/analysis | 2 | 20.0 |
Complement 1 Inactivators/*biosynthesis/genetics | 2 | 100.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Testosterone/*pharmacology | 2 | 6.0 |
Actins/*genetics | 4 | 6.0 |
Collagen/*genetics | 2 | 0.0 |
von Willebrand Factor/*genetics | 2 | 2.0 |
Chromatography, DEAE-Cellulose | 2 | 3.0 |
Electroencephalography | 4 | 1.0 |
Kidney/physiopathology | 2 | 3.0 |
*Postoperative Care | 2 | 12.0 |
Spinal Cord Diseases/*physiopathology | 3 | 75.0 |
Blood Sedimentation | 2 | 1.0 |
C-Reactive Protein/analysis | 4 | 0.0 |
Antibodies | 5 | 1.0 |
Blood Grouping and Crossmatching | 3 | 4.0 |
Complement 2/*genetics/immunology | 2 | 100.0 |
Ethnic Groups | 2 | 0.0 |
Isoelectric Focusing/methods | 3 | 10.0 |
Cyclosporine/blood/*pharmacokinetics | 3 | 50.0 |
Immunosuppressive Agents/blood/*pharmacokinetics | 3 | 33.0 |
Kidney Transplantation/*physiology | 3 | 6.0 |
Complement 2/analysis/*genetics | 2 | 100.0 |
Complement Factor B/analysis/*genetics | 2 | 33.0 |
Autoantibodies/analysis | 4 | 2.0 |
Salmonella/*immunology | 4 | 80.0 |
KB Cells | 2 | 2.0 |
Complement/analysis/*physiology | 2 | 66.0 |
Mice/*immunology | 2 | 22.0 |
Heart Catheterization | 2 | 3.0 |
Immunoglobulin A/analysis | 2 | 1.0 |
*Ribonucleoproteins | 6 | 16.0 |
Hela Cells/immunology | 2 | 14.0 |
Complement/physiology | 3 | 6.0 |
Complement 5/*physiology | 2 | 33.0 |
Palliative Care | 2 | 4.0 |
Cholinesterases/*blood | 2 | 11.0 |
Isoelectric Point | 4 | 3.0 |
Arthritis, Rheumatoid/immunology | 6 | 6.0 |
Complement 1q | 24 | 23.0 |
Complement Activating Enzymes/metabolism | 7 | 25.0 |
Edetic Acid | 6 | 14.0 |
Complement 1/*biosynthesis | 3 | 100.0 |
*Complement Inactivators | 12 | 15.0 |
Plasmin/metabolism | 3 | 3.0 |
Erythrocyte Membrane/*metabolism | 2 | 2.0 |
Antigen-Antibody Complex/metabolism | 4 | 7.0 |
Lupus Erythematosus, Systemic/etiology | 2 | 66.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Collagen/analysis | 2 | 2.0 |
Mitomycin | 2 | 4.0 |
DNA, Recombinant | 3 | 1.0 |
Immunoglobulin M/metabolism | 4 | 4.0 |
Complement 3 Convertase/*metabolism | 9 | 52.0 |
Complement Activating Enzymes/*metabolism | 13 | 41.0 |
Liver Neoplasms/metabolism | 2 | 2.0 |
Atrophy | 2 | 1.0 |
Splenectomy | 2 | 3.0 |
Angioneurotic Edema/*etiology/immunology/therapy | 2 | 100.0 |
Muscles/*physiology | 2 | 7.0 |
Adenocarcinoma/radiotherapy/surgery/*therapy | 2 | 66.0 |
Cecal Neoplasms/radiotherapy/surgery/*therapy | 2 | 100.0 |
Lupus Erythematosus, Systemic/*genetics | 2 | 3.0 |
Monocytes/drug effects/immunology/*metabolism | 2 | 15.0 |
Complement 2/*genetics/isolation & purification | 2 | 100.0 |
DNA/*isolation & purification | 2 | 5.0 |
Haplorhini | 3 | 1.0 |
Densitometry | 2 | 1.0 |
Lupus Erythematosus, Systemic/blood | 2 | 7.0 |
Blood Proteins/isolation & purification/*metabolism | 2 | 22.0 |
Immunoelectrophoresis | 24 | 10.0 |
Antigen-Antibody Complex/immunology | 7 | 12.0 |
Complement Membrane Attack Complex | 4 | 5.0 |
HLA-DR2 Antigen | 2 | 10.0 |
Multiple Sclerosis/genetics/*immunology | 3 | 15.0 |
Cytotoxicity Tests, Immunologic | 4 | 0.0 |
HLA-DR Antigens/*analysis | 2 | 1.0 |
Skin Diseases, Vesiculobullous/*immunology | 2 | 9.0 |
Ribonucleoproteins/*isolation & purification | 3 | 100.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
CCAAT-Enhancer-Binding Proteins/genetics/*metabolism | 2 | 10.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
*Form Perception | 2 | 20.0 |
Mental Retardation/*psychology | 2 | 50.0 |
Laboratory Techniques and Procedures | 2 | 6.0 |
Microscopy | 2 | 7.0 |
Complement 4b | 23 | 24.0 |
Serine Endopeptidases/genetics | 2 | 5.0 |
Complement Factor B/analysis | 9 | 20.0 |
Cervical Vertebrae/*anatomy & histology/physiology | 2 | 100.0 |
Aging | 3 | 0.0 |
Complement/*deficiency/physiology | 2 | 100.0 |
Complement 4/physiology | 2 | 40.0 |
Complement Activating Enzymes | 5 | 35.0 |
Salmonella | 2 | 8.0 |
Properdin/*biosynthesis | 2 | 66.0 |
Complement/deficiency/*metabolism | 3 | 100.0 |
Complement 3 Convertase/*blood | 2 | 100.0 |
Complement Activating Enzymes/*blood | 2 | 33.0 |
Macrophage-1 Antigen | 4 | 8.0 |
Angioneurotic Edema/complications | 3 | 100.0 |
Complement Activating Enzymes/deficiency | 4 | 66.0 |
Taxoids/*chemical synthesis/chemistry/pharmacology | 2 | 100.0 |
*Bone Density | 2 | 1.0 |
Postmenopause | 2 | 1.0 |
Carbohydrates/analysis | 3 | 4.0 |
Neuraminidase | 2 | 5.0 |
Globins/*genetics | 2 | 1.0 |
Gorilla gorilla/genetics | 2 | 7.0 |
HLA-D Antigens/*analysis | 2 | 3.0 |
Germany, West | 4 | 8.0 |
*Paternity | 2 | 2.0 |
Antibodies, Bacterial/physiology | 2 | 28.0 |
*Glycoproteins | 4 | 0.0 |
Aphidicolin | 2 | 22.0 |
Diterpenes/pharmacology | 2 | 7.0 |
Agglutination Tests | 2 | 4.0 |
Complement 2/*analysis/deficiency/immunology | 2 | 100.0 |
Shock, Septic/immunology | 2 | 20.0 |
Antigen-Antibody Complex | 13 | 7.0 |
Placenta/metabolism | 2 | 1.0 |
*IgG Deficiency | 2 | 40.0 |
Immunization, Passive | 3 | 3.0 |
Immunoglobulin Allotypes/genetics | 2 | 11.0 |
Complement 5/biosynthesis | 2 | 20.0 |
Complement 5a | 2 | 6.0 |
Monocytes/metabolism | 2 | 0.0 |
DNA Restriction Enzymes | 3 | 0.0 |
Complement 2/isolation & purification/*metabolism | 3 | 75.0 |
Glycoside Hydrolases | 2 | 7.0 |
Complement 4/isolation & purification | 5 | 83.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Testosterone/blood | 2 | 0.0 |
Cholesterol/blood/genetics | 2 | 33.0 |
Israel | 2 | 1.0 |
Lipoproteins, HDL Cholesterol/blood/genetics | 2 | 15.0 |
Lipoproteins, LDL Cholesterol/blood/genetics | 2 | 28.0 |
Triglycerides/blood/genetics | 2 | 25.0 |
Histocompatibility Antigens/*analysis | 4 | 8.0 |
Lactoylglutathione Lyase/*genetics | 8 | 19.0 |
Lyases/*genetics | 8 | 16.0 |
Angioneurotic Edema/*blood/genetics | 2 | 100.0 |
Complement/analysis/immunology | 2 | 33.0 |
Immunoglobulins, Fab/immunology | 4 | 3.0 |
Finland/ethnology | 2 | 22.0 |
Antigen-Antibody Complex/*analysis | 3 | 1.0 |
Immunosuppressive Agents/*blood/pharmacokinetics/therapeutic use | 2 | 100.0 |
Complement 3 | 11 | 27.0 |
Complement 4 | 11 | 61.0 |
Macrophages/*immunology | 4 | 1.0 |
Receptors, Complement 3b | 9 | 2.0 |
Multicenter Studies | 2 | 1.0 |
Triptorelin | 2 | 14.0 |
Complement 3b/genetics | 3 | 75.0 |
Leukocytes/analysis | 2 | 33.0 |
Complement 3 Convertase/blood | 2 | 28.0 |
Lupus Erythematosus, Systemic/*blood/immunology | 2 | 10.0 |
Freeze Drying | 2 | 8.0 |
Complement Activating Enzymes/*genetics | 2 | 33.0 |
*Peptide Biosynthesis | 2 | 6.0 |
Nerve Growth Factors/*pharmacology | 2 | 1.0 |
Complement 3b/*metabolism | 4 | 4.0 |
Monocytes/drug effects/*metabolism | 4 | 3.0 |
Tetrodotoxin/pharmacology | 2 | 5.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
HLA-D Antigens/*genetics | 2 | 1.0 |
Complement/metabolism | 9 | 9.0 |
Complement Inactivators/*blood | 2 | 28.0 |
*Evoked Potentials, Somatosensory | 5 | 17.0 |
Complement 4a | 11 | 18.0 |
Antibodies, Monoclonal/diagnostic use | 4 | 0.0 |
*HLA-B Antigens | 3 | 5.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Adenocarcinoma/drug therapy/*radiotherapy/surgery | 2 | 100.0 |
Irrigation | 3 | 5.0 |
Canada | 3 | 2.0 |
Erythrocytes/*enzymology | 3 | 0.0 |
Autoantigens/*immunology | 2 | 1.0 |
*RNA, Small Cytoplasmic | 4 | 15.0 |
Complement 1s | 9 | 40.0 |
*Genes | 4 | 1.0 |
Monocytes/cytology/*metabolism | 2 | 7.0 |
Ribonucleoproteins/*genetics | 2 | 4.0 |
Casein Kinases | 2 | 4.0 |
Complement 2/isolation & purification | 3 | 100.0 |
Complement 3/isolation & purification | 3 | 100.0 |
Complement 3 Convertase/*biosynthesis | 2 | 66.0 |
Complement Activating Enzymes/*biosynthesis | 4 | 57.0 |
Erythrocytes/enzymology | 2 | 0.0 |
Lactoferrin/*pharmacology | 2 | 8.0 |
Lactoglobulins/*pharmacology | 2 | 25.0 |
Antibodies/pharmacology | 2 | 0.0 |
Complement 1/analysis | 18 | 36.0 |
Sulfhydryl Reagents/*pharmacology | 3 | 14.0 |
Glycoproteins/genetics | 3 | 3.0 |
Cervical Vertebrae/*injuries/radiography | 2 | 100.0 |
Fractures/*radiography | 2 | 100.0 |
Autoimmune Diseases/genetics | 4 | 15.0 |
Multiple Sclerosis/*genetics/immunology | 2 | 11.0 |
Rectal Neoplasms/*radiotherapy/surgery | 4 | 100.0 |
Lactoylglutathione Lyase/genetics | 7 | 16.0 |
Feedback | 2 | 1.0 |
*Hemoglobin, Sickle | 2 | 33.0 |
Complement/*analysis/immunology | 3 | 33.0 |
HLA-A Antigens | 7 | 2.0 |
HLA-B Antigens | 13 | 3.0 |
Hemoglobins, Abnormal/*analysis | 2 | 10.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 6 | 12.0 |
Complement 1/*isolation & purification | 2 | 66.0 |
Complement 4/*analysis | 2 | 4.0 |
Erythrocytes | 2 | 4.0 |
Immunoassay/*methods | 2 | 2.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Cytoplasm/metabolism | 3 | 0.0 |
*Complement 2 | 4 | 80.0 |
Complement Factor B | 7 | 58.0 |
Calcium Chloride/pharmacology | 2 | 9.0 |
Histidine | 3 | 6.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
Complement 3 Convertase | 3 | 33.0 |
Adrenal Hyperplasia, Congenital/*genetics | 3 | 13.0 |
*Deoxyribonucleases, Type II Site-Specific | 2 | 3.0 |
Complement 2/*immunology | 4 | 80.0 |
Immunoelectrophoresis, Two-Dimensional | 7 | 5.0 |
Dialysis | 2 | 4.0 |
Lymphokines/*pharmacology | 2 | 0.0 |
Complement/deficiency/metabolism/*physiology | 2 | 100.0 |
Immunologic Deficiency Syndromes/genetics/immunology | 2 | 28.0 |
Hemoglobin A | 3 | 42.0 |
*Histidine | 2 | 11.0 |
Glomerulonephritis/immunology | 2 | 8.0 |
Angioneurotic Edema/*complications | 2 | 100.0 |
Complement 2/*analysis/deficiency | 3 | 100.0 |
*HLA Antigens/genetics | 2 | 8.0 |
HLA-DR Antigens | 17 | 4.0 |
Angioneurotic Edema/genetics/immunology | 2 | 66.0 |
Complement 1r | 7 | 30.0 |
Complement Factor B/*metabolism | 4 | 33.0 |
Liver Neoplasms/secondary | 3 | 4.0 |
Logistic Models | 3 | 0.0 |
C-Reactive Protein/*metabolism | 2 | 0.0 |
Immunoglobulin G/physiology | 3 | 15.0 |
Pregnancy Complications/*immunology | 2 | 15.0 |
Lipids/*blood | 3 | 0.0 |
Blood Bactericidal Activity | 3 | 3.0 |
Transferrin/analysis | 2 | 2.0 |
Histocompatibility Antigens Class II/*genetics | 4 | 2.0 |
Hemoglobins, Abnormal/*analysis/genetics | 2 | 28.0 |
Sulfhydryl Compounds | 2 | 8.0 |
Complement 5/genetics | 2 | 50.0 |
Complement Activating Enzymes/genetics | 2 | 100.0 |
*Chromosomes, Human, 6-12 and X | 6 | 4.0 |
*Cell Membrane Permeability | 2 | 8.0 |
Complement 4/biosynthesis/genetics | 3 | 75.0 |
Macrophages/immunology | 6 | 2.0 |
Phagocytes/*immunology | 3 | 9.0 |
Complement 1/*immunology | 2 | 33.0 |
Complement 4/*immunology | 4 | 21.0 |
Sheep/blood | 2 | 14.0 |
Antigens/*immunology | 2 | 2.0 |
DNA/immunology | 2 | 4.0 |
Complement 4/analysis/deficiency/*genetics | 2 | 66.0 |
Histocompatibility Antigens Class II/*analysis | 2 | 1.0 |
*Lymphocyte Culture Test, Mixed | 2 | 3.0 |
Abortion, Habitual/*genetics | 2 | 9.0 |
*Selection (Genetics) | 2 | 3.0 |
Muramidase/biosynthesis | 2 | 33.0 |
Protein Precursors/metabolism | 2 | 1.0 |
Complement 4/*genetics/immunology | 2 | 16.0 |
Electrophoresis, Cellulose Acetate | 3 | 7.0 |
Hemagglutinins/*isolation & purification/metabolism | 2 | 100.0 |
Acetyl-CoA Carboxylase/*genetics | 2 | 25.0 |
Skin/enzymology | 2 | 6.0 |
HLA-DR3 Antigen | 4 | 10.0 |
Complement/*genetics/immunology | 2 | 100.0 |
Complement 3b Inactivators/genetics | 2 | 100.0 |
Phagocytes/immunology | 2 | 8.0 |
Receptors, Complement/immunology | 2 | 6.0 |
*Haploidy | 2 | 14.0 |
Complement 1 Inactivators/immunology | 2 | 66.0 |
Complement Activating Enzymes/immunology | 3 | 30.0 |
Complement 3/deficiency | 6 | 35.0 |
Complement 5/deficiency | 3 | 30.0 |
*Antibodies | 3 | 6.0 |
Immune Sera/pharmacology | 2 | 2.0 |
Pulmonary Alveoli/cytology | 2 | 9.0 |
Superoxides/biosynthesis | 2 | 20.0 |
Chromosomes, Human, 6-12 and X | 8 | 18.0 |
HLA Antigens/*analysis | 4 | 0.0 |
Monocytes/drug effects/*immunology | 3 | 4.0 |
Erythrocytes/*metabolism | 3 | 1.0 |
Cell Communication | 2 | 0.0 |
Complement 3b Inactivators/pharmacology | 4 | 36.0 |
Complement 2 | 9 | 90.0 |
Complement 5 | 2 | 18.0 |
Complement Factor D | 2 | 100.0 |
Endopeptidases/metabolism | 3 | 2.0 |
Angioneurotic Edema/*blood/genetics/immunology | 2 | 100.0 |
*Immunologic Techniques | 2 | 6.0 |
Complement 3a | 2 | 8.0 |
Japan/ethnology | 2 | 2.0 |
Hela Cells/analysis | 4 | 36.0 |
Complement 1 | 7 | 50.0 |
Carrier Proteins/pharmacology | 2 | 3.0 |
Complement 3 Convertase/antagonists & inhibitors | 2 | 25.0 |
Antigen-Antibody Reactions/drug effects | 2 | 14.0 |
Cold | 2 | 1.0 |
Complement/*genetics/physiology | 2 | 66.0 |
Horses | 2 | 1.0 |
Lipopolysaccharides/immunology | 2 | 1.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 4 | 8.0 |
Complement 2/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
HLA-DR4 Antigen | 2 | 3.0 |
Norway | 2 | 1.0 |
Cell Membrane/immunology | 7 | 2.0 |
Receptors, Complement | 3 | 30.0 |
Chloromercuribenzoates/pharmacology | 2 | 28.0 |
Iodine/*pharmacology | 2 | 50.0 |
p-Chloromercuribenzoic Acid | 2 | 50.0 |
Enterovirus Infections/*epidemiology | 2 | 66.0 |
Rectal Neoplasms/radiotherapy/*surgery | 2 | 100.0 |
HLA-C Antigens | 3 | 2.0 |
Complement 4/genetics/*immunology | 2 | 28.0 |
Blood Bactericidal Activity/*drug effects | 2 | 28.0 |
Centrifugation, Density Gradient | 6 | 1.0 |
Iodine/pharmacology | 2 | 66.0 |
Chromatography, Agarose | 4 | 8.0 |
Complement Factor B/isolation & purification | 2 | 66.0 |
Azlocillin | 2 | 100.0 |
Methicillin/*pharmacology | 2 | 40.0 |
Oxacillin/*pharmacology | 2 | 50.0 |
Penicillin G/*pharmacology | 2 | 100.0 |
Penicillins/*pharmacology | 2 | 13.0 |
Erythrocyte Membrane/*immunology | 2 | 4.0 |
Glucose/*immunology | 2 | 100.0 |
Hemagglutinins/*immunology | 3 | 50.0 |
Isoantibodies/*analysis | 2 | 8.0 |
Blood Group Antigens/*genetics | 2 | 1.0 |
Neuraminidase/analysis | 2 | 100.0 |
Blood Proteins/analysis | 2 | 1.0 |
Alcohol Dehydrogenase/genetics/*immunology/isolation & purification | 2 | 100.0 |
Horses/immunology/metabolism | 2 | 100.0 |
Isoenzymes/*immunology/isolation & purification | 2 | 100.0 |
Mice, Inbred BALB C/genetics/*immunology/metabolism | 2 | 100.0 |
Stomach/enzymology | 2 | 14.0 |
Lymphocyte Culture Test, Mixed | 9 | 1.0 |
Complement 4/antagonists & inhibitors | 2 | 100.0 |
Endotoxins/analysis | 2 | 20.0 |
Complement Activating Enzymes/analysis | 4 | 13.0 |
*Amino Acid Sequence | 2 | 12.0 |
Glomerulonephritis/*genetics/immunology | 3 | 42.0 |
Zymosan | 2 | 9.0 |
Cyclooxygenase Inhibitors | 3 | 18.0 |
*Dust | 2 | 14.0 |
Crossing Over, Genetic | 4 | 5.0 |
Bacteria/drug effects | 2 | 18.0 |
Lymphocytes/*immunology | 4 | 0.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Cross-Linking Reagents/pharmacology | 2 | 1.0 |
Monocytes/*immunology/metabolism | 3 | 8.0 |
Complement 2/*analysis/isolation & purification | 2 | 100.0 |
Erythrocytes/metabolism | 4 | 2.0 |
Complement 7/analysis | 5 | 45.0 |
Complement 6/analysis | 7 | 53.0 |
Monocytes/cytology/*immunology | 2 | 5.0 |
Complement 5/analysis | 11 | 25.0 |
Carbohydrates/pharmacology | 2 | 18.0 |
Kidney/immunology | 2 | 4.0 |
Lupus Erythematosus, Systemic/genetics/*immunology/pathology | 2 | 66.0 |
Immunity, Natural | 2 | 0.0 |
Cryoglobulins/analysis | 3 | 27.0 |
Monocytes/immunology/*metabolism | 2 | 4.0 |
Opsonins/*physiology | 3 | 37.0 |
Lymphocytes/immunology | 3 | 0.0 |
Agammaglobulinemia/immunology | 5 | 38.0 |
Complement Inactivators/metabolism | 2 | 10.0 |
Evoked Potentials, Somatosensory | 2 | 15.0 |
Histidine/*analysis | 2 | 66.0 |
Neuraminidase/*pharmacology | 2 | 25.0 |
Monocytes/*immunology/metabolism/ultrastructure | 2 | 66.0 |
Lysosomes/enzymology | 3 | 4.0 |
Membranes/immunology | 3 | 30.0 |
Mucopolysaccharidoses/*diagnosis | 2 | 100.0 |
Skin/*enzymology | 2 | 8.0 |
Immune Sera/isolation & purification | 4 | 50.0 |
Complement 3b Inactivators/deficiency | 2 | 100.0 |
Properdin | 2 | 33.0 |
Blood Proteins/biosynthesis | 4 | 19.0 |
Immunologic Deficiency Syndromes/*genetics | 4 | 13.0 |
Antibodies, Antinuclear | 2 | 28.0 |
HLA Antigens | 9 | 6.0 |
Neutrophils | 3 | 4.0 |
China/ethnology | 2 | 1.0 |
Blood Group Antigens | 2 | 5.0 |
Cornea/*immunology | 2 | 16.0 |
Complement 1/*deficiency | 2 | 66.0 |
Complement 1 Inactivators/analysis | 2 | 22.0 |
Complement Activation/*radiation effects | 2 | 100.0 |
Reye Syndrome/*immunology | 2 | 100.0 |
Stomatitis/immunology | 2 | 100.0 |
Virus Diseases/immunology | 3 | 15.0 |
Macaca | 2 | 2.0 |
Exertion | 2 | 2.0 |
Cryoglobulins/*analysis | 2 | 28.0 |
Consanguinity | 3 | 0.0 |
Histamine/*pharmacology | 2 | 5.0 |
*Complement 4 | 2 | 25.0 |
Glomerulonephritis/*immunology/pathology | 2 | 13.0 |
Synovial Fluid/immunology | 4 | 10.0 |
*Antigen-Antibody Complex | 6 | 10.0 |
*Cereals | 2 | 20.0 |
Commerce | 2 | 100.0 |
Antibodies, Viral/analysis | 2 | 1.0 |
*Cryoglobulins | 4 | 80.0 |
Basement Membrane/immunology | 2 | 3.0 |
Chelating Agents | 2 | 9.0 |
Endotoxins | 2 | 9.0 |
Complement 1 Inactivators | 3 | 42.0 |
Immunoglobulin M/analysis | 3 | 1.0 |
Immunoglobulin M | 3 | 10.0 |
Complement/*analysis/metabolism | 3 | 42.0 |
Whales | 2 | 28.0 |
Antigens | 3 | 3.0 |
Sheep/immunology | 7 | 29.0 |
Magnesium | 3 | 12.0 |
Opsonins/*immunology | 2 | 11.0 |
Arthritis, Rheumatoid/genetics | 2 | 18.0 |
*HLA Antigens | 10 | 4.0 |
Lupus Erythematosus, Systemic/*complications/immunology/pathology | 2 | 66.0 |
Properdin/physiology | 2 | 33.0 |
Fluorescence Polarization Immunoassay | 2 | 16.0 |
Apoptosis/*physiology | 2 | 0.0 |
Lupus Erythematosus, Systemic/complications/immunology | 2 | 50.0 |
Paraproteinemias/*immunology | 2 | 10.0 |
Properdin/*metabolism | 2 | 20.0 |
Long-Term Care | 2 | 3.0 |
Iodine Radioisotopes | 3 | 0.0 |
*Histocompatibility Antigens | 9 | 12.0 |
*Complement Fixation Tests | 2 | 28.0 |
*Properdin | 2 | 50.0 |
*Complement/analysis | 3 | 37.0 |
Immunologic Deficiency Syndromes/*genetics/immunology | 2 | 13.0 |
Laboratories/standards | 2 | 11.0 |
Bacteriolysis | 2 | 33.0 |
*Complement/metabolism | 2 | 100.0 |
Histamine Release | 3 | 5.0 |
Synovial Fluid/*immunology | 2 | 3.0 |
Goats/immunology | 3 | 14.0 |
Calcium | 2 | 7.0 |
Guinea Pigs/immunology | 4 | 26.0 |
Cyclosporine/*pharmacokinetics | 3 | 27.0 |
Fasting | 2 | 0.0 |
